9,466 results on '"Myocardial Infarction"'
Search Results
2. Percutaneous Coronary Revascularization Strategies After Myocardial Infarction: A Systematic Review and Network Meta-Analysis.
- Author
-
Reddy, Rohin K., Howard, James P., Jamil, Yasser, Madhavan, Mahesh V., Nanna, Michael G., Lansky, Alexandra J., Leon, Martin B., and Ahmad, Yousif
- Subjects
- *
MYOCARDIAL infarction , *ST elevation myocardial infarction , *CORONARY artery disease , *PERCUTANEOUS coronary intervention , *ACUTE kidney failure - Abstract
Complete revascularization with percutaneous coronary intervention improves outcomes compared with culprit revascularization following myocardial infarction (MI) with multivessel coronary artery disease. An all-cause mortality reduction has never been demonstrated. Debate also remains regarding the optimal timing of complete revascularization (immediate or staged), and method of evaluation of nonculprit lesions (physiology or angiography). This study aims to perform an updated systematic review with frequentist and Bayesian network meta-analyses including the totality of randomized data investigating revascularization strategies in patients presenting with MI and multivessel coronary artery disease. The primary comparison tested complete vs culprit revascularization. Timing and methods of achieving complete revascularization were assessed. The prespecified primary outcome was all-cause mortality. Outcomes were expressed as relative risk (RR) (95% CI). Twenty-four eligible trials randomized 16,371 patients (weighted mean follow-up: 26.4 months). Compared with culprit revascularization, complete revascularization reduced all-cause mortality in patients with any MI (RR: 0.85; 95% CI: 0.74-0.99; P = 0.04). Cardiovascular mortality, MI, major adverse cardiac events and repeat revascularization were also significantly reduced. In patients presenting with ST-segment elevation myocardial infarction, the point estimate for all-cause mortality with complete revascularization was RR: 0.91 (95% CI: 0.78-1.05; P = 0.18). Rates of stent thrombosis, major bleeding, and acute kidney injury were similar. Immediate complete revascularization ranked higher than staged complete revascularization for all endpoints. Complete revascularization following MI reduces all-cause mortality, cardiovascular mortality, MI, major adverse cardiac events, and repeat revascularization. There may be benefits to immediate complete revascularization, but additional head-to-head trials are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs.
- Author
-
Lincoff, A. Michael, Ray, Kausik K., Sasiela, William J., Haddad, Tariq, Nicholls, Stephen J., Li, Na, Cho, Leslie, Mason, Denise, Libby, Peter, Goodman, Shaun G., and Nissen, Steven E.
- Subjects
- *
STATINS (Cardiovascular agents) , *MAJOR adverse cardiovascular events , *LDL cholesterol , *HYDROXYCHOLESTEROLS , *MYOCARDIAL infarction , *CORONARY disease , *PRASUGREL - Abstract
In the CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Outcomes trial, treatment of statin-intolerant patients with bempedoic acid produced a 21% decrease in low-density lipoprotein cholesterol (LDL-C) relative to placebo and a 13% relative reduction in the risk of major adverse cardiovascular events. This study sought to determine whether the relationship between LDL-C lowering and cardiovascular benefit achieved with bempedoic acid resembles that observed with statins when standardized per unit change in LDL-C. To compare the treatment effect of bempedoic acid with statins, the methodology of the Cholesterol Treatment Trialists' Collaboration (CTTC) was applied to outcomes among the 13,970 patients enrolled in the CLEAR Outcomes trial. The CTTC endpoint of "major vascular event" was a composite of coronary heart disease death, nonfatal myocardial infarction, fatal or nonfatal stroke, or coronary revascularization. HRs for CTTC-defined endpoints were normalized to 1 mmol/L differences in LDL-C levels between bempedoic acid and placebo groups. A first major vascular event occurred in 703 (10.1%) patients in the bempedoic acid group and 816 (11.7%) patients in the placebo group (HR: 0.85; 95% CI: 0.77-0.94). When normalized per 1 mmol/L reduction in LDL-C, the HR was 0.75 (95% CI: 0.63-0.90), comparable to the rate ratio of 0.78 reported for statins in the CTTC meta-analysis. Normalized risk reductions were similar for bempedoic acid and statins for the endpoints of major coronary events, nonfatal myocardial infarction, and coronary revascularization. Cardiovascular risk reduction with bempedoic acid is similar to that achieved with statins for a given absolute magnitude of LDL-C lowering. (Evaluation of Major Adverse Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated with Bempedoic Acid [ETC-1002] or Placebo [CLEAR Outcomes]; NCT02993406). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Coronary Artery Bypass Graft Failure in Women: Incidence and Clinical Implications.
- Author
-
Sandner, Sigrid, Redfors, Björn, An, Kevin R., Harik, Lamia, Heise, Rachel, Di Franco, Antonino, Fremes, Stephen E., Hare, David L., Kulik, Alexander, Lamy, Andre, Peper, Joyce, Ruel, Marc, ten Berg, Jurrien M., Willemsen, Laura M., Zhao, Qiang, Zhu, Yunpeng, Wojdyla, Daniel M., Bhatt, Deepak L., Alexander, John H., and Gaudino, Mario
- Subjects
- *
MYOCARDIAL infarction , *CORONARY artery bypass , *CORONARY artery surgery , *CLINICAL trials , *DRUG-eluting stents - Abstract
Women have worse outcomes after coronary artery bypass surgery (CABG) than men. This study aimed to determine the incidence of CABG graft failure in women, its association with cardiac events, and whether it contributes to sex-related differences in outcomes. A pooled analysis of individual patient data from randomized clinical trials with systematic imaging follow-up was performed. Multivariable logistic regression models were used to assess the association of graft failure with myocardial infarction and repeat revascularization between CABG and imaging (primary outcome) and death after imaging (secondary outcome). Mediation analysis was performed to evaluate the effect of graft failure on the association between female sex and risk of death. Seven randomized clinical trials (N = 4,413, 777 women) were included. At a median imaging follow-up of 1.03 years, graft failure was significantly more frequent among women than men (37.3% vs 32.9% at the patient-level and 20.5% vs 15.8% at the graft level; P = 0.02 and P < 0.001, respectively). In women, graft failure was associated with an increased risk of myocardial infarction and repeat revascularization (OR: 3.94; 95% CI: 1.79-8.67) and death (OR: 3.18; 95% CI: 1.73-5.85). Female sex was independently associated with the risk of death (direct effect, HR: 1.84; 95% CI: 1.35-2.50) but the association was not mediated by graft failure (indirect effect, HR: 1.04; 95% CI: 0.86-1.26). Graft failure is more frequent in women and is associated with adverse cardiac events. The excess mortality risk associated with female sex among CABG patients is not mediated by graft failure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. The roles of B cells in cardiovascular diseases.
- Author
-
Ma, Jian, Wang, Xiaotong, Jia, Yuewang, Tan, Fangyan, Yuan, Xin, and Du, Jianlin
- Subjects
- *
B cells , *CARDIOVASCULAR diseases , *HEART cells , *HEART fibrosis , *HEART failure , *MYOCARDIAL infarction - Abstract
Damage to the heart can start the repair process and cause cardiac remodeling. B cells play an important role in this process. B cells are recruited to the injured place and activate cardiac remodeling through secreting antibodies and cytokines. Different types of B cells showed specific functions in the heart. Among all types of B cells, heart-associated B cells play a vital role in the heart by secreting TGFβ1. B cells participate in the activation of fibroblasts and promote cardiac fibrosis. Four subtypes of B cells in the heart revealed the relationship between the B cells' heterogeneity and cardiac remodeling. Many cardiovascular diseases like atherosclerosis, heart failure (HF), hypertension, myocardial infarction (MI), and dilated cardiomyopathy (DCM) are related to B cells. The primary mechanisms of these B cell-related activities will be discussed in this review, which may also suggest potential novel therapeutic targets. • We summarized the relationship between B cells and cardiac remodeling. • In different cardiovascular diseases, B cells express different biomarkers and play different roles in cardiac fibrosis. • According to the mechanism of B cell action, potential therapeutic targets were proposed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Lithium versus anticonvulsants and the risk of physical disorders – Results from a comprehensive long-term nation-wide population-based study emulating a target trial.
- Author
-
Kessing, Lars Vedel, Knudsen, Mark Bech, Rytgaard, Helene Charlotte Wiese, Torp-Pedersen, Christian, and Berk, Michael
- Subjects
- *
ANTICONVULSANTS , *LITHIUM carbonate , *PARKINSON'S disease , *CHRONIC kidney failure , *MYOCARDIAL infarction , *EMPAGLIFLOZIN , *PHENOBARBITAL - Abstract
Bipolar disorder is associated with increased rates of many physical disorders, but the effects of medication are unclear. We systematically investigated the associations between sustained use of first line maintenance agents, lithium versus lamotrigine and valproate, and the risk of physical disorders using a nation-wide population-based target trial emulation covering the entire 5.9 million inhabitants in Denmark. We identified two cohorts. Cohort 1: patients with a diagnosis of bipolar disorder prior to first purchase (N = 12.607). Cohort 2: all 156.678 adult patients who had their first ever purchase (since 1995) of either lithium, lamotrigine or valproate between 1997 and 2021 regardless of diagnosis. Main analyses investigated the effect of sustained exposure defined as exposure for all consecutive 6-months periods during a 10-year follow-up. Outcomes included a diagnosis of incident stroke, arteriosclerosis, angina pectoris, myocardial infarction, diabetes mellitus, myxedema, osteoporosis, dementia, Parkinson's disease, chronic kidney disease and cancer (including subtypes). In both Cohorts 1 and 2, there were no systematic statistically significant differences in associations between sustained use of lithium versus lamotrigine and valproate, respectively, and any physical disorder, including subtypes of disorders, except myxedema, for which exposure to lithium increased the absolute risk of myxedema with 7–10 % compared with lamotrigine or valproate. In conclusion, these analyses emulating a target trial of "real world" observational register-based data show that lithium does not increase the risk of developing any kind of physical disorders, except myxedema, which may be a result of detection bias. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. The correlation of atherogenic index of plasma with non-obstructive CAD and unfavorable prognosis among patients diagnosed with MINOCA.
- Author
-
Abdu, Fuad A., Alifu, Jiasuer, Mohammed, Abdul-Quddus, Liu, Lu, Zhang, Wen, Yin, Guoqing, Lv, Xian, Mohammed, Ayman A., Mareai, Redhwan M., Xu, Yawei, and Che, Wenliang
- Subjects
- *
DYSLIPIDEMIA , *CORONARY artery stenosis , *MYOCARDIAL infarction , *CARDIOVASCULAR diseases , *CORONARY artery disease , *PROGNOSIS - Abstract
• The atherogenic index of plasma (AIP) is linked to lipid metabolism and has shown considerable prognostic value in cardiovascular disorders. • The prognostic impact of AIP among myocardial infarction with the non-obstructive coronary artery (MINOCA) has not been investigated. • Our results showed that AIP is an independent predictor of MACE in MINOCA patients, even though they generally exhibit a lower prevalence of dyslipidemia. • High AIP was significantly associated with increased risk of non-obstructive CAD in MINOCA. The atherogenic index of plasma (AIP) is linked to lipid metabolism and has shown considerable prognostic value in cardiovascular disorders. However, its role in myocardial infarction with non-obstructive coronary arteries (MINOCA) has not been investigated. We assessed the relationship between AIP, the severity of coronary stenosis, and prognosis in MINOCA. We included consecutive patients who were diagnosed with MINOCA. AIP was calculated using the base 10 logarithm of the ratio between the levels of TG and HDL-C. The patients were divided into four groups based on their AIP quartiles: Q1 (AIP<-0.145), Q2 (AIP≥-0.145and≤0.049), Q3 (AIP>0.049and≤0.253), and Q4 (AIP>0.253). All patients underwent follow-up for MACE. The final analysis included 421 patients, with 188 having normal coronaries (0 stenosis) and 233 exhibiting non-obstructive coronary artery disease (CAD) (<50 % stenosis). In the multivariate logistic analysis, highest AIP (Q4) group was significantly associated with increased risk of non-obstructive CAD in MINOCA (OR,1.994;95 % CI:1.075–3.698; P = 0.029). During the follow-up period, MACE occurred in 22.8 % of MINOCA patients. Q4 group exhibited a significantly higher rate of MACE (P = 0.021). Furthermore, when both AIP and coronary stenosis status were considered, the results revealed individuals in the Q4 group with non-obstructive CAD had the highest risk of MACE (log-rank P = 0.027). The adjusted Cox analysis indicated that the Q4 group was associated with a 2.052-fold increase in the HR of MACE. AIP exhibits a notable association with the incidence of MACE in MINOCA patients and serves as a substantial marker for non-obstructive CAD in this patient group. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. The impact of colchicine on patients with acute and chronic coronary artery disease.
- Author
-
Madanchi, Mehdi, Young, Mabelle, Tersalvi, Gregorio, Maria Cioffi, Giacomo, Attinger-Toller, Adrian, Cuculi, Florim, Kurmann, Reto, and Bossard, Matthias
- Subjects
- *
CORONARY artery disease , *COLCHICINE , *MYOCARDIAL infarction , *SECONDARY prevention , *ANTI-inflammatory agents - Abstract
• Inflammation plays a key role in the development coronary artery disease (CAD). • The ancient drug colchicine targets inflammation through multiple pathways. • Recent trials indicated that colchicine reduces the risk for ischemic events in CAD. • Albeit colchicine is safe, it may be underused for secondary prevention in CAD. • More data is needed to define the optimal duration of colchicine therapy in CAD. Inflammation plays a central role in coronary artery disease (CAD), and recent data have shown that anti-inflammatory drugs have the potential to reduce ischemic events in CAD patients. Colchicine is an ancient anti-inflammatory drug that targets neutrophil and inflammasome activities. It has been prescribed for decades for different rheumatological conditions. Given the important role of inflammation in the development of cardiovascular disease, there has been considerable interest in studying colchicine's potential to limit the progression of atherosclerosis among afflicted patients. In fact, there is a growing body of randomized data suggesting that use of low-dose colchicine reduces the risk of ischemic events in patients with CAD, particularly repeated revascularizations, new myocardial infarctions and strokes. This review article summarizes background information—including possible side effects and contraindications—as well as the current evidence backing up the use of colchicine in patients with established CAD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. ALKBH5 induces fibroblast-to-myofibroblast transformation during hypoxia to protect against cardiac rupture after myocardial infarction.
- Author
-
Yang, Kun, Zhao, Yongchao, Hu, Jingjing, Gao, Rifeng, Shi, Jiaran, Wei, Xiang, Chen, Juntao, Hu, Kai, Sun, Aijun, and Ge, Junbo
- Subjects
- *
MYOCARDIAL infarction , *HYPOXEMIA , *HEART size , *FIBROBLASTS , *GENETIC transcription regulation , *IMMUNOPRECIPITATION - Abstract
[Display omitted] • ALKBH5 plays an important protective role during the post-MI repair phase. • The loss of ALKBH5 in fibroblasts leads to cardiac rupture and deteriorated cardiac function. • This study identities the ALKBH5 as hypoxia-related role in cardiac fibroblasts. • ALKBH5 regulates fibroblast activation via ErbB4 mRNA demethylation. • ALKBH5/ErbB4 are possible therapeutic targets to reduce the occurrence of cardiac rupture. N6-methyladenosine (m6A) methylation produces a marked effect on cardiovascular diseases. The m6A demethylase AlkB homolog 5 (ALKBH5), as an m6A "eraser", is responsible for decreased m6A modification. However, its role in cardiac fibroblasts during the post-myocardial infarction (MI) healing process remains elusive. To investigate the effect of ALKBH5 in cardiac fibroblasts during infarct repair. MI was mimicked by permanent left anterior descending artery ligation in global ALKBH5-knockout, ALKBH5-knockin, and fibroblast-specific ALKBH5-knockout mice to study the function of ALKBH5 during post-MI collagen repair. Methylated RNA immunoprecipitation sequencing was performed to explore potential ALKBH5 targets. Dramatic alterations in ALKBH5 expression were observed during the early stages post-MI and in hypoxic fibroblasts. Global ALKBH5 knockin reduced infarct size and ameliorated cardiac function after MI. The global and fibroblast-specific ALKBH5-knockout mice both exhibited low survival rates along with poor collagen repair, impaired cardiac function, and cardiac rupture. Both in vivo and in vitro ALKBH5 loss resulted in impaired fibroblast activation and decreased collagen deposition. Additionally, hypoxia, but not TGF-β1 or Ang II, upregulated ALKBH5 expression in myofibroblasts by HIF-1α-dependent transcriptional regulation. Mechanistically, ALKBH5 promoted the stability of ErbB4 mRNA and the degradation of ST14 mRNA via m6A demethylation. Fibroblast-specific ErbB4 overexpression ameliorated the impaired fibroblast-to-myofibroblast transformation and poor post-MI repair due to ALKBH5 knockout. Fibroblast ALKBH5 positively regulates post-MI healing by stabilization of ErbB4 mRNA in an m6A-dependent manner. ALKBH5/ErbB4 might be potential therapeutic targets for post-MI cardiac rupture. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Symptoms as a Predictor of the Placebo-Controlled Efficacy of PCI in Stable Coronary Artery Disease.
- Author
-
Simader, Florentina A., Rajkumar, Christopher A., Foley, Michael J., Ahmed-Jushuf, Fiyyaz, Chotai, Shayna, Bual, Nina, Khokhar, Arif, Gohar, Aisha, Lampadakis, Ioannis, Ganesananthan, Sashiananthan, Pathimagaraj, Rachel H., Nowbar, Alexandra, Davies, John R., Keeble, Tom R., O'Kane, Peter D., Haworth, Peter, Routledge, Helen, Kotecha, Tushar, Spratt, James C., and Williams, Rupert
- Subjects
- *
CORONARY artery disease , *STRESS echocardiography , *PERCUTANEOUS coronary intervention , *CORONARY angiography , *SYMPTOMS , *MYOCARDIAL infarction , *CHEST pain - Abstract
Placebo-controlled evidence from ORBITA-2 (Objective Randomised Blinded Investigation with Optimal Medical Therapy of Angioplasty in Stable Angina-2) found that percutaneous coronary intervention (PCI) in stable coronary artery disease with little or no antianginal medication relieved angina, but residual symptoms persisted in many patients. The reason for this was unclear. This ORBITA-2 secondary analysis investigates the relationship between presenting symptoms and disease severity (anatomic, noninvasive, and invasive ischemia) and the ability of symptoms to predict the placebo-controlled efficacy of PCI. Prerandomization symptom severity and nature were assessed using the ORBITA smartphone application and symptom and quality of life questionnaires including the World Health Organization Rose angina questionnaire (Rose). Disease severity was assessed using quantitative coronary angiography, stress echocardiography, fractional flow reserve, and instantaneous wave-free ratio. Bayesian ordinal regression was used. At prerandomization, the median number of daily angina episodes was 0.8 (Q1-Q3: 0.4-1.6), 64% had Rose angina, quantitative coronary angiography diameter stenosis was 61% (Q1-Q3: 49%-74%), stress echocardiography score was 1.0 (Q1-Q3: 0.0-2.7), fractional flow reserve was 0.63 (Q1-Q3: 0.49–0.75), and instantaneous wave-free ratio was 0.78 (Q1-Q3: 0.55-0.87). There was little relationship between symptom severity and nature and disease severity: angina symptom score with quantitative coronary angiography ordinal correlation coefficient: 0.06 (95% credible interval [CrI]: 0.00-0.08); stress echocardiography: 0.09 (95% CrI: 0.02-0.10); fractional flow reserve: 0.04 (95% CrI: −0.03 to 0.07); and instantaneous wave-free ratio: 0.04 (95% CrI: −0.01 to 0.07). However, Rose angina and guideline-based typical angina were strong predictors of placebo-controlled PCI efficacy (angina symptom score: OR: 1.9; 95% CrI: 1.6-2.1; probability of interaction [Pr Interaction ] = 99.9%; and OR: 1.8; 95% CrI: 1.6-2.1; Pr Interaction = 99.9%, respectively). Although symptom severity and nature were poorly associated with disease severity, the nature of symptoms powerfully predicted the placebo-controlled efficacy of PCI. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Data-driven personalized medicine approaches to cognitive-behavioral therapy allocation in a large sample: A reanalysis of the ENRICHED study.
- Author
-
van Bronswijk, Suzanne Catharina, Howard, Jacqueline, and Lorenzo-Luaces, Lorenzo
- Subjects
- *
COGNITIVE therapy , *MENTAL health services , *INDIVIDUALIZED medicine , *PSYCHOTHERAPY , *MYOCARDIAL infarction , *POST-traumatic stress - Abstract
Although effective treatments for common mental health problems are available, individual responses to treatments are difficult to predict. Treatment efficacy could be optimized by targeting interventions using individual predictions of treatment outcomes. The aim of this study was to develop a prediction algorithm using data from one of the largest randomized controlled trials on psychological interventions for common mental health problems. This is a secondary analysis of the Enhancing Recovery in Coronary Heart Disease study investigating the effectiveness of cognitive behavioral therapy (CBT) and care as usual (CAU) for depression and low perceived social support following acute myocardial infarction. 2481 participants were randomly assigned to CBT and CAU. Baseline social-demographics, depression characteristics, comorbid symptoms, and stress and adversity measures were used to build an algorithm predicting post-treatment depression severity using elastic net regularization. Performance and generalizability of this algorithm were determined in a hold-out sample (n = 1203). Treatment matching based on predictions in the hold-out sample resulted in inconsistent and small effects (d = 0.15), that were more pronounced for individuals matched to CBT (d = 0.22). We identified a small subgroup of individuals for which CBT did not appear more efficacious than CAU. Limitations are a poorly defined CAU condition, a low-severity sample, specific exclusion criteria and unavailability of certain baseline variables. Small matching effects are likely a realistic representation of the performance and generalizability of multivariable prediction algorithms based on clinical measures. Results indicate that future work and new approaches are needed. • Machine learning predictions were made for targeted psychological interventions. • Predictions relied on self-report and clinical observation. • Predictions were developed and tested in a large dataset. • Predictions resulted in small matching effects. • Improvements are needed to guarantee clinical relevance of these prediction models. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. US trends of in-hospital morbidity and mortality for acute myocardial infarctions complicated by cardiogenic shock.
- Author
-
Koester, Margaret, Dangl, Michael, Albosta, Michael, Grant, Jelani, Maning, Jennifer, and Colombo, Rosario
- Subjects
- *
CARDIOGENIC shock , *MYOCARDIAL infarction , *NON-ST elevated myocardial infarction , *HOSPITAL mortality , *INTRA-aortic balloon counterpulsation , *ARTIFICIAL blood circulation - Abstract
There is limited real-world data highlighting recent temporal in-hospital morbidity and mortality trends for cases of acute myocardial infarction complicated by cardiogenic shock. The role of mechanical circulatory support within this patient population remains unclear. The US National Inpatient Sample database was sampled from 2011 to 2018 identifying 206,396 hospitalizations with a primary admission diagnosis of ST- or Non-ST elevation myocardial infarction complicated by cardiogenic shock. The primary outcomes included trends of all-cause in-hospital mortality, mechanical circulatory support use, and sex-specific trends for acute myocardial infarction complicated by cardiogenic shock (AMI-CS) over the study period. The annual number of AMI-CS hospitalizations increased from 22,851 in 2011 to 30,015 in 2018 and in-hospital mortality trends remained similar (42.9 % to 43.7 %, ptrend < 0.001). The proportion of patients receiving any temporary MCS device decreased (46.4 % to 44.4 %). The use of intra-aortic balloon pump (IABP) decreased (44.9 % to 32.9 %) and the use of any other non-IABP MCS device increased (2.5 % to 15.6 %), ptrend<0.001. Sex-specific mortality indicate female in-hospital mortality remained similar (50.3 % to 51 %, ptrend<0.001), but higher than male in-hospital mortality, which increased non-significantly (38.8 % to 40.2 %, ptrend = 0.372). From 2011 to 2018, hospitalizations for AMI-CS patients have increased in number. However, there has been no recent appreciable change in AMI-CS mortality despite a changing treatment landscape with decreasing use of IABPs and increasing use of non-IABP MCS devices. Further research is necessary to examine the appropriate use of MCS devices within this population. • AMI complicated by cardiogenic shock (AMI-CS) is a highly morbid condition. • The number of AMI-CS cases has increased from 22,851 in 2011 to 30,015 in 2018 and mortality has remained unchanged at 40–45%. • Intra-aortic balloon pump use in AMI-CS patients is decreasing (44.9% to 32.9%, p-value<0.001). • Use of other temporary mechanical circulatory devices is increasing (2.5% to 15.6%, p-value<0.001). • Mortality of female AMI-CS patients is consistently nearly 10 % higher than males. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Impact of hyperuricemia on 5-year clinical outcomes following percutaneous transluminal angioplasty.
- Author
-
Ahn, Woo Jin, An, Seong Joon, Rha, Seung-Woon, Park, Soohyung, Hyun, Su Jin, Cha, Jin Ah, Byun, Jae Kyeong, Choi, Se Yeon, Choi, Cheol Ung, Oh, Dong Joo, and Choi, Byoung Geol
- Subjects
- *
TRANSLUMINAL angioplasty , *HYPERURICEMIA , *PERIPHERAL vascular diseases , *TREATMENT effectiveness , *MYOCARDIAL infarction - Abstract
Although the correlation between hyperuricemia and cardiovascular disease (CVD) is well known, there have been limited data regarding the impact of hyperuricemia on long-term clinical outcomes in patients with peripheral arterial disease (PAD) after percutaneous transluminal angioplasty (PTA). A total of 718 patients who underwent PTA for PAD were enrolled. The patients were divided into the hyperuricemia group (N = 168) and the normal group (N = 550). Hyperuricemia was defined as a uric acid level ≥ 7.0 mg/dL in men, and ≥ 6.5 mg/dL in women. The primary endpoint was major adverse cerebral and cardiovascular event (MACCE), including death, myocardial infarction (MI), any coronary revascularization, and stroke, up to 5 years. The secondary endpoint was major adverse limb event (MALE), including any repeated PTA, and target extremity surgery (TES). Inverse probability weighting (IPTW) analysis, derived from the logistic regression model, was performed to adjust potential confounders. After IPTW matching analysis, compared to the normal group, the hyperuricemia group was not associated with increased MACCE but was associated with an increased incidence of MI (2.6 % vs. 0.5 %, p = 0.001), and coronary revascularization (6.7 % vs. 3.9 %, p = 0.018). Also, the hyperuricemia group was associated with a higher incidence of MALE (45.3 % vs. 28.9 %, p < 0.001), including target extremity revascularization (TER; 25.1 % vs. 15.9 %, p < 0.001), non-TER (11.5 % vs. 5.6 %, p < 0.001), and TES (22.8 % vs. 16.2 %, p = 0.002). In the present study, hyperuricemia was associated with worse clinical outcomes in PAD patients following PTA during 5-year clinical follow-up. Further investigations should be made regarding the clinical benefit of controlling hyperuricemia on clinical outcomes. [Display omitted] • Hyperuricemia was associated with worse clinical outcomes in PAD patients who underwent PTA, with higher incidence of MALE. • Subgroup analysis revealed 16% increased risk of MALE for every 1 mg/dL of uric acid, demonstrating dose-respond trend. • Assessing levels of uric acid in PAD patients could contribute to additional risk stratification. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Enhancing myocardial infarction treatment through bionic hydrogel-mediated spatial combination therapy via mtDNA-STING crosstalk modulation.
- Author
-
Zheng, Zhi, Sun, Jian, Wang, Jun, He, Suisui, Liu, Zhenqiu, Xie, Jiahao, Yu, Cui-Yun, and Wei, Hua
- Subjects
- *
MYOCARDIAL infarction , *MITOCHONDRIAL DNA , *MYOCARDIAL injury , *BIOMIMETICS , *BIONICS , *HEART failure , *GINSENOSIDES , *INSECT bites & stings - Abstract
Myocardial infarction (MI)-induced impaired cardiomyocyte (CM) mitochondrial function and microenvironmental inflammatory cascades severely accelerate the progression of heart failure for compromised myocardial repair. Modulation of the crosstalk between CM mitochondrial DNA (mtDNA) and STING has been recently identified as a robust strategy in enhancing MI treatment, but remains seldom explored. To develop a novel approach that can address persistent myocardial injury using this crosstalk, we report herein construction of a biomimetic hydrogel system, Rb1/PDA-hydrogel comprised of ginsenoside Rb1/polydopamine nanoparticles (Rb1/PDA NPs)-loaded carboxylated chitosan, 4-arm-PEG-phenylboronic acid (4-arm-PEG-PBA), and 4-arm-PEG-dopamine (4-arm-PEG-DA) crosslinked networks. An optimized hydrogel formulation presents not only desired adhesion properties to the surface of the myocardium, but also adaptability for deep myocardial injection, resulting in ROS scavenging, CM mitochondrial function protection, M1 macrophage polarization inhibition through the STING pathway, and angiogenesis promotion via an internal-external spatial combination. The enhanced therapeutic efficiency is supported by the histological analysis of the infarcted area, which shows that the fibrotic area of the MI rats decreases from 58.4% to 5.5%, the thickness of the left ventricular wall increases by 1-fold, and almost complete recovery of cardiac function after 28 days of treatment. Overall, this study reported the first use of a strong adhesive and injectable hydrogel with mtDNA and STING signaling characteristics for enhanced MI treatment via an internal-external spatial combination strategy. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. 10-Year Mortality After ST-Segment Elevation Myocardial Infarction Compared to the General Population.
- Author
-
Thrane, Pernille Gro, Olesen, Kevin Kris Warnakula, Thim, Troels, Gyldenkerne, Christine, Hansen, Malene Kærslund, Stødkilde-Jørgensen, Nina, Jakobsen, Lars, Bødtker Mortensen, Martin, Dalby Kristensen, Steen, and Maeng, Michael
- Subjects
- *
ST elevation myocardial infarction , *PERCUTANEOUS coronary intervention , *MORTALITY - Abstract
ST-segment elevation myocardial infarction (STEMI) is associated with high early mortality. However, it remains unclear if patients surviving the early phase have long-term excess mortality. This study aims to assess excess mortality in STEMI patients treated with primary percutaneous coronary intervention (PCI) compared with an age- and- sex-matched general population at landmark periods 0 to 30 days, 31 to 90 days, and 91 days to 10 years. Using the Western Denmark Heart Registry, we identified first-time PCI-treated patients who had primary PCI for STEMI from January 2003 to October 2018. Each patient was matched by age and sex to 5 individuals from the general population. We included 18,818 patients with first-time STEMI and 94,090 individuals from the general population. Baseline comorbidity burden was similar in STEMI patients and matched individuals. Compared with the matched individuals, STEMI was associated with a 5.9% excess mortality from 0 to 30 days (6.0% vs 0.2%; HR: 36.44; 95% CI: 30.86-43.04). An excess mortality remained present from 31 to 90 days (0.9% vs 0.4%; HR: 2.43; 95% CI: 2.02-2.93). However, in 90-day STEMI survivors, the absolute excess mortality was only 2.1 percentage points at 10-year follow-up (26.5% vs 24.5%; HR: 1.04; 95% CI: 1.01-1.08). Use of secondary preventive medications such as statins, antiplatelet therapy, and beta-blockers was very high in STEMI patients throughout 10-year follow-up. In primary PCI-treated STEMI patients with high use of guideline-recommended therapy, patients surviving the first 90 days had 10-year mortality that was only 2% higher than that of a matched general population. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Excess Apolipoprotein B and Cardiovascular Risk in Women and Men.
- Author
-
Johannesen, Camilla Ditlev Lindhardt, Langsted, Anne, Nordestgaard, Børge Grønne, and Mortensen, Martin Bødtker
- Subjects
- *
APOLIPOPROTEIN B , *CARDIOVASCULAR diseases risk factors , *LDL cholesterol , *MYOCARDIAL infarction , *LIPOPROTEINS - Abstract
Low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) are highly correlated measures of atherogenic lipoproteins. The study investigators hypothesized that excess apoB is associated with an increased risk of myocardial infarction (MI), atherosclerotic cardiovascular disease (ASCVD), and all-cause mortality. The study included 53,484 women and 41,624 men not taking statins from the Copenhagen General Population Study. Associations of excess apoB with the risk of MI, ASCVD, and all-cause mortality were estimated by Cox proportional hazards regressions with 95% CIs. Excess apoB was defined as measured levels of apoB minus expected levels of apoB from LDL-C alone; expected levels were defined by linear regressions of LDL-C levels vs apoB levels in individuals with triglycerides ≤1 mmol/L (89 mg/dL). During a median follow-up of 9.6 years, 2,048 MIs, 4,282 ASCVD events, and 8,873 deaths occurred. There was a dose-dependent association between excess apoB and the risk of MI and ASCVD in both women and men, as well as an association with the risk of all-cause mortality in women. For ASCVD in women compared with those with excess apoB <11 mg/dL, the multivariable adjusted HR was 1.08 (95% CI: 0.97-1.21) for excess apoB 11 to 25 mg/dL, 1.30 (95% CI: 1.14-1.48) for 26 to 45 mg/dL, 1.34 (95% CI: 1.14-1.58) for 46 to 100 mg/dL, and 1.75 (95% CI: 1.08-2.83) for excess apoB >100 mg/dL. Corresponding HRs in men were 1.14 (95% CI: 1.02-1.26), 1.41 (95% CI: 1.26-1.57), 1.41 (95% CI: 1.25-1.60), and 1.52 (95% CI: 1.13-2.05), respectively. Results were robust across the entire LDL-C spectrum. Excess apoB (ie, the value of apoB above that contributed by LDL-C levels alone) is associated dose-dependently with an increased risk of MI and ASCVD in women and men. This finding demonstrates that apoB provides important predictive value beyond LDL-C across the entire LDL-C spectrum. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.
- Author
-
Udell, Jacob A., Petrie, Mark C., Jones, W. Schuyler, Anker, Stefan D., Harrington, Josephine, Mattheus, Michaela, Seide, Svenja, Amir, Offer, Bahit, M. Cecilia, Bauersachs, Johann, Bayes-Genis, Antoni, Chen, Yundai, Chopra, Vijay K., Figtree, Gemma, Ge, Junbo, Goodman, Shaun G., Gotcheva, Nina, Goto, Shinya, Gasior, Tomasz, and Jamal, Waheed
- Subjects
- *
HEART failure , *MYOCARDIAL infarction , *VENTRICULAR ejection fraction , *EMPAGLIFLOZIN , *HEART failure patients , *LEFT ventricular dysfunction - Abstract
Empagliflozin reduces the risk of heart failure (HF) hospitalizations but not all-cause mortality when started within 14 days of acute myocardial infarction (AMI). This study sought to evaluate the association of left ventricular ejection fraction (LVEF), congestion, or both, with outcomes and the impact of empagliflozin in reducing HF risk post-AMI. In the EMPACT-MI (Trial to Evaluate the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction) trial, patients were randomized within 14 days of an AMI complicated by either newly reduced LVEF<45%, congestion, or both, to empagliflozin (10 mg daily) or placebo and were followed up for a median of 17.9 months. Among 6,522 patients, the mean baseline LVEF was 41 ± 9%; 2,648 patients (40.6%) presented with LVEF <45% alone, 1,483 (22.7%) presented with congestion alone, and 2,181 (33.4%) presented with both. Among patients in the placebo arm of the trial, multivariable adjusted risk for each 10-point reduction in LVEF included all-cause death or HF hospitalization (HR: 1.49; 95% CI: 1.31-1.69; P < 0.0001), first HF hospitalization (HR: 1.64; 95% CI: 1.37-1.96; P < 0.0001), and total HF hospitalizations (rate ratio [RR]: 1.89; 95% CI: 1.51-2.36; P < 0.0001). The presence of congestion was also associated with a significantly higher risk for each of these outcomes (HR: 1.52, 1.94, and RR: 2.03, respectively). Empagliflozin reduced the risk for first (HR: 0.77; 95% CI: 0.60-0.98) and total (RR: 0.67; 95% CI: 0.50-0.89) HF hospitalizations, irrespective of LVEF or congestion, or both. The safety profile of empagliflozin was consistent across baseline LVEF and irrespective of congestion status. In patients with AMI, the severity of left ventricular dysfunction and the presence of congestion was associated with worse outcomes. Empagliflozin reduced first and total HF hospitalizations across the range of LVEF with and without congestion. (Trial to Evaluate the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction [EMPACT-MI]; NCT04509674) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Randomized Trial of Remote Assessment of Patients After an Acute Coronary Syndrome.
- Author
-
Alshahrani, Nasser S., Hartley, Adam, Howard, James, Hajhosseiny, Reza, Khawaja, Saud, Seligman, Henry, Akbari, Tamim, Alharbi, Badr A., Bassett, Paul, Al-Lamee, Rasha, Francis, Darrel, Kaura, Amit, Kelshiker, Mihir A., Peters, Nicholas S., and Khamis, Ramzi
- Subjects
- *
ACUTE coronary syndrome , *EMERGENCY room visits , *CHEST pain , *MAJOR adverse cardiovascular events , *CARDIOVASCULAR diseases risk factors , *PATIENT readmissions , *TELERADIOLOGY - Abstract
Telemedicine programs can provide remote diagnostic information to aid clinical decisions that could optimize care and reduce unplanned readmissions post–acute coronary syndrome (ACS). TELE-ACS (Remote Acute Assessment of Patients With High Cardiovascular Risk Post-Acute Coronary Syndrome) is a randomized controlled trial that aims to compare a telemedicine-based approach vs standard care in patients following ACS. Patients were suitable for inclusion with at least 1 cardiovascular risk factor and presenting with ACS and were randomized (1:1) before discharge. The primary outcome was time to first readmission at 6 months. Secondary outcomes included emergency department (ED) visits, major adverse cardiovascular events, and patient-reported symptoms. The primary analysis was performed according to intention to treat. A total of 337 patients were randomized from January 2022 to April 2023, with a 3.6% drop-out rate. The mean age was 58.1 years. There was a reduced rate of readmission over 6 months (HR: 0.24; 95% CI: 0.13-0.44; P < 0.001) and ED attendance (HR: 0.59; 95% CI: 0.40-0.89) in the telemedicine arm, and fewer unplanned coronary revascularizations (3% in telemedicine arm vs 9% in standard therapy arm). The occurrence of chest pain (9% vs 24%), breathlessness (21% vs 39%), and dizziness (6% vs 18%) at 6 months was lower in the telemedicine group. The TELE-ACS study has shown that a telemedicine-based approach for the management of patients following ACS was associated with a reduction in hospital readmission, ED visits, unplanned coronary revascularization, and patient-reported symptoms. (Telemedicine in High-Risk Cardiovascular Patients Post-ACS [TELE-ACS]; NCT05015634) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Enhancing HDL Function to Prevent Atherothrombosis: Is it Time to Efflux the HDL Hypothesis?
- Author
-
Finn, Aloke V.
- Subjects
- *
ACUTE coronary syndrome , *MYOCARDIAL infarction , *HYPOTHESIS - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Reperfusion Injury in Patients With Acute Myocardial Infarction: JACC Scientific Statement.
- Author
-
Welt, Frederick G.P., Batchelor, Wayne, Spears, J. Richard, Penna, Claudia, Pagliaro, Pasquale, Ibanez, Borja, Drakos, Stavros G., Dangas, George, and Kapur, Navin K.
- Subjects
- *
MYOCARDIAL infarction , *REPERFUSION injury , *ST elevation myocardial infarction , *ENDOTHELIUM diseases , *MYOCARDIAL injury - Abstract
Despite impressive improvements in the care of patients with ST-segment elevation myocardial infarction, mortality remains high. Reperfusion is necessary for myocardial salvage, but the abrupt return of flow sets off a cascade of injurious processes that can lead to further necrosis. This has been termed myocardial ischemia-reperfusion injury and is the subject of this review. The pathologic and molecular bases for myocardial ischemia-reperfusion injury are increasingly understood and include injury from reactive oxygen species, inflammation, calcium overload, endothelial dysfunction, and impaired microvascular flow. A variety of pharmacologic strategies have been developed that have worked well in preclinical models and some have shown promise in the clinical setting. In addition, there are newer mechanical approaches including mechanical unloading of the heart prior to reperfusion that are in current clinical trials. [Display omitted] • MIRI exacerbates myocardial necrosis in patients with STEMI, contributing to mortality. • MIRI is mediated by varying combinations of ROS, inflammation, endothelial dysfunction, impaired microvascular flow, and other factors. • A variety of pharmacologic and mechanical strategies that mitigate MIRI in preclinical models have shown promise in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Coronary Atherosclerotic Plaque Activity and Risk of Myocardial Infarction.
- Author
-
Wang, Kang-Ling, Balmforth, Craig, Meah, Mohammed N., Daghem, Marwa, Moss, Alastair J., Tzolos, Evangelos, Kwiecinski, Jacek, Molek-Dziadosz, Patrycja, Craig, Neil, Bularga, Anda, Adamson, Philip D., Dawson, Dana K., Arumugam, Parthiban, Sabharwal, Nikant K., Greenwood, John P., Townend, Jonathan N., Calvert, Patrick A., Rudd, James H.F., Verjans, Johan W., and Berman, Daniel S.
- Subjects
- *
MYOCARDIAL infarction , *ATHEROSCLEROTIC plaque , *POSITRON emission tomography , *CORONARY artery disease , *CORONARY arteries - Abstract
Total coronary atherosclerotic plaque activity across the entire coronary arterial tree is associated with patient-level clinical outcomes. We aimed to investigate whether vessel-level coronary atherosclerotic plaque activity is associated with vessel-level myocardial infarction. In this secondary analysis of an international multicenter study of patients with recent myocardial infarction and multivessel coronary artery disease, we assessed vessel-level coronary atherosclerotic plaque activity using coronary 18F-sodium fluoride positron emission tomography to identify vessel-level myocardial infarction. Increased 18F-sodium fluoride uptake was found in 679 of 2,094 coronary arteries and 414 of 691 patients. Myocardial infarction occurred in 24 (4%) vessels with increased coronary atherosclerotic plaque activity and in 25 (2%) vessels without increased coronary atherosclerotic plaque activity (HR: 2.08; 95% CI: 1.16-3.72; P = 0.013). This association was not demonstrable in those treated with coronary revascularization (HR: 1.02; 95% CI: 0.47-2.25) but was notable in untreated vessels (HR: 3.86; 95% CI: 1.63-9.10; P interaction = 0.024). Increased coronary atherosclerotic plaque activity in multiple coronary arteries was associated with heightened patient-level risk of cardiac death or myocardial infarction (HR: 2.43; 95% CI: 1.37-4.30; P = 0.002) as well as first (HR: 2.19; 95% CI: 1.18-4.06; P = 0.013) and total (HR: 2.50; 95% CI: 1.42-4.39; P = 0.002) myocardial infarctions. In patients with recent myocardial infarction and multivessel coronary artery disease, coronary atherosclerotic plaque activity prognosticates individual coronary arteries and patients at risk for myocardial infarction. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.
- Author
-
Povsic, Thomas J., Korjian, Serge, Bahit, M. Cecilia, Chi, Gerald, Duffy, Danielle, Alexander, John H., Vinereanu, Dragos, Tricoci, Pierluigi, Mears, Sojaita Jenny, Deckelbaum, Lawrence I., Bonaca, Marc, Ridker, Paul M., Goodman, Shaun G., Cornel, Jan H., Lewis, Basil S., Parkhomenko, Alexander, Lopes, Renato D., Aylward, Philip, Lincoff, A. Michael, and Heise, Mark
- Subjects
- *
APOLIPOPROTEIN A , *MYOCARDIAL infarction , *ACUTE coronary syndrome - Abstract
The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk of plaque disruption, decreasing the risk of recurrent events such as myocardial infarction (MI) among high-risk patients with MI. This exploratory analysis evaluates the effect of CSL112 therapy on the incidence of cardiovascular (CV) death and recurrent MI. The AEGIS-II trial was an international, multicenter, randomized, double-blind, placebo-controlled trial that randomized 18,219 high-risk acute MI patients to 4 weekly infusions of apoA-I (6 g CSL112) or placebo. The incidence of the composite of CV death and type 1 MI was 11% to 16% lower in the CSL112 group over the study period (HR: 0.84; 95% CI: 0.7-1.0; P = 0.056 at day 90; HR: 0.86; 95% CI: 0.74-0.99; P = 0.048 at day 180; and HR: 0.89; 95% CI: 0.79-1.01; P = 0.07 at day 365). Similarly, the incidence of CV death or any MI was numerically lower in CSL112-treated patients throughout the follow-up period (HR: 0.92; 95% CI: 0.80-1.05 at day 90, HR: 0.89; 95% CI: 0.79-0.996 at day 180, HR: 0.91; 95% CI: 0.83-1.01 at day 365). The effect of CSL112 treatment on MI was predominantly observed for type 1 MI and type 4b (MI due to stent thrombosis). Although CSL112 did not significantly reduce the occurrence of the primary study endpoints, patients treated with CSL112 infusions had numerically lower rates of CV death and MI, type-1 MI, and stent thrombosis–related MI compared with placebo. These findings could suggest a role of apoA-I in reducing subsequent plaque disruption events via enhanced cholesterol efflux. Further prospective data would be needed to confirm these observations. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Metabolome analyses of skin dialysate: Insights into skin interstitial fluid biomarkers.
- Author
-
Oharazawa, Akihiko, Maimaituxun, Gulinu, Watanabe, Koichi, Nishiyasu, Takeshi, and Fujii, Naoto
- Subjects
- *
EXTRACELLULAR fluid , *MYOCARDIAL infarction , *SKIN tests , *PROTON magnetic resonance spectroscopy , *EARLY detection of cancer , *BIOMARKERS , *ALZHEIMER'S disease - Abstract
Metabolites in biofluids can serve as biomarkers for diagnosing diseases and monitoring body conditions. Among the available biofluids, interstitial fluid (ISF) in the skin has garnered considerable attention owing to its advantages, which include inability to clot, easy access to the skin, and possibility of incorporating wearable devices. However, the scientific understanding of skin ISF composition is limited. In this study, we aimed to compare metabolites between skin dialysate containing metabolites from the skin ISF and venous blood (plasma) samples, both collected under resting states. We collected forearm skin dialysate using intradermal microdialysis alongside venous blood (plasma) samples from 12 healthy young adults. We analyzed these samples using capillary electrophoresis–fourier transform mass spectrometry–based metabolomics (CE–FTMS). Significant positive correlations were observed in 39 metabolites between the skin dialysate and plasma, including creatine (a mitochondrial disease biomarker), 1-methyladenosine (an early detection of cancer biomarker), and trimethylamine N-oxide (a posterior predictor of heart failure biomarker). Based on the Human Metabolome Technologies database, we identified 12 metabolites unique to forearm skin dialysate including nucleic acids, benzoate acids, fatty acids, amino acids, ascorbic acid, 3-methoxy-4-hydroxyphenylethyleneglycol (an Alzheimer's disease biomarker), and cysteic acid (an acute myocardial infarction biomarker). We show that some venous blood biomarkers may be predicted from skin dialysate or skin ISF, and that these fluids may serve as diagnostic and monitoring tools for health and clinical conditions. • Skin interstitial fluid offers non-clotting, easy access from the skin surface. • Identified 12 key metabolites in skin dialysate by using CE–FTMS–based metabolomics. • Skin dialysate positively correlates with plasma in 39 metabolites. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Nocturnal oxygen resaturation parameters are associated with cardiorespiratory comorbidities.
- Author
-
Howarth, Timothy P., Sillanmäki, Saara, Karhu, Tuomas, Rissanen, Marika, Islind, Anna Sigridur, Hrubos-Strøm, Harald, de Chazal, Philip, Huovila, Juuso, Kainulainen, Samu, and Leppänen, Timo
- Subjects
- *
OXYGEN saturation , *COMORBIDITY , *HYPOGLYCEMIC agents , *MYOCARDIAL infarction , *HEART failure - Abstract
There are strong associations between oxygen desaturations and cardiovascular outcomes. Additionally, oxygen resaturation rates are linked to excessive daytime sleepiness independent of oxygen desaturation severity. No studies have yet looked at the independent effects of comorbidities or medications on resaturation parameters. The Sleep Heart Health Study data was utilised to derive oxygen saturation parameters from 5804 participants. Participants with a history of comorbidities or medication usage were compared against healthy participants with no comorbidity/medication history. 4293 participants (50.4% female, median age 64 years) were included in the analysis. Females recorded significantly faster resaturation rates (mean 0.61%/s) than males (mean 0.57%/s, p < 0.001), regardless of comorbidities. After adjusting for demographics, sleep parameters, and desaturation parameters, resaturation rate was reduced with hypertension (-0.09 (95% CI -0.16, -0.03)), myocardial infarction (-0.13 (95% CI -0.21, -0.04)) and heart failure (-0.19 (95% CI -0.33, -0.05)), or when using anti-hypertensives (-0.10 (95% CI -0.17, -0.03)), mental health medications (-0.18 (95% CI -0.27, -0.08)) or anticoagulants (-0.41 (95% CI -0.56, -0.26)). Desaturation to Resaturation ratio for duration was decreased with mental health (-0.21 (95% CI -0.34, -0.08)) or diabetic medications (-0.24 (95% CI -0.41, -0.07)), and desaturation to resaturation ratio for area decreased with heart failure (-0.25 (95% CI -0.42, -0.08)). Comorbidities and medications significantly affect nocturnal resaturation parameters, independent of desaturation parameters. However, the causal relationship remains unclear. Further research can enhance our knowledge and develop more precise and safer interventions for individuals affected by certain comorbidities. • Oxygen resaturation rate is faster in females (0.61 %/s) than in males (0.57 %/s). • Oxygen resaturation rate is slowed with hypertension or myocardial infarction. • Mental health medications and anticoagulants significantly slowed resaturation rates. • Resaturation rate was not associated with ESS scores. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis.
- Author
-
Mahajan, Kunal, Nagendra, Lakshmi, Dhall, Anil, and Dutta, Deep
- Subjects
- *
ACUTE coronary syndrome , *LDL cholesterol , *EZETIMIBE , *MYOCARDIAL infarction , *ISCHEMIC stroke - Abstract
• Ezetimibe with statins during acute coronary syndrome associated with better outcomes. • An addition lowering of LDL-C by 19.55 mg/dl seen at 7-days. • Peak additional LDL-C lowering by 24.67 mg/dl seen by 1-month. • Durable additional LDL-C lowering by 18.0 mg/dl seen by 3-months therapy. • Durable additional LDL-C lowering by 16.90 mg/dl seen by 10–12-months therapy. Scant data is available on the efficacy and safety of adding ezetimibe to high-intensity statin therapy for early and rapid reduction of low-density lipoprotein cholesterol (LDL-C) within 4–12 weeks of an acute-event in acute coronary syndrome (ACS). We undertook this meta-analysis to address this knowledge-gap. Electronic databases were searched for RCTs involving patients with ACS receiving ezetimibe in intervention arm, and placebo/active comparator in control arm. Primary outcome was to evaluate changes in LDL-C levels post-ACS. Secondary outcomes were to evaluate alterations in other lipid parameters and adverse events. From initially screened 4561 articles, data from 11 studies (20,291 patients) were analyzed. Compared to controls, patients receiving ezetimibe had significantly lower LDL-C at 7-days [MD -19.55 mg/dl(95 %CI:–36.46 to –2.63); P = 0.02; I 2 = 91 %], 1-month [MD-24.67 mg/dl (95 %CI:–34.59 to –14.76); P < 0.001; I 2 = 81 %], 3-months [MD -18.01 mg/dl(95 %CI:–24.11 to –11.90); P < 0.001; I 2 = 92 %] and 10–12 months [MD -16.90 mg/dl (95 % CI: –17.67 to –16.12); P < 0.001; I 2 = 0 %] of treatment. Compared to controls, patients receiving ezetimibe had significantly lower total cholesterol at 7-days [MD-21.05 mg/dl(95 %CI:–26.73 to –15.37); P < 0.001; I 2 = 0 %], 1-month [MD-25.56 mg/dl(95 %CI:–38.29 to –12.83); P < 0.001; I 2 = 85 %], 3-months [MD-22.54 mg/dl(95 %CI:–36.90 to –8.19); P = 0.002; I 2 = 22 %] and 12-months [MD-19.68 mg/dl(95 %CI:–20.78 to –18.59); P < 0.001; I 2 = 0 %] of treatment. Death from any cause, ACS and non-fatal stroke [OR0.89(95 %CI:0.83–0.96); P = 0.002; I 2 = 0 %], non-fatal myocardial infarction [OR0.86(95 %CI:0.79–0.94); P = 0.001; I 2 = 0 %] and ischemic stroke [OR0.80(95 %CI:0.68–0.94); P = 0.009; I 2 = 0 %] was significantly reduced in patients receiving ezetimibe. Addition of ezetimibe to high-intensity statin therapy at the time of ACS event is associated with significantly better cholesterol reduction at day-7,1-month, 3- months and 1-year of follow-up, which translates into a significantly lower recurrent cardiovascular events post an index event of ACS. Addition of ezetimibe to high-intensity statin therapy at the time of acute coronary syndrome (ACS) index event is associated with significantly better low density lipoprotein cholesterol and total cholesterol reduction at day-7, 1-month, 3-months and 1-year of follow-up, which translates into a significantly lower recurrent cardiovascular events (death from any cause, major ACS, non-fatal stroke, non-fatal myocardial infarction, and ischemic stroke) post an index event of ACS. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Chronic Total Occlusions: A State-of-the-Art Review.
- Author
-
O'Brien, Joseph M., Dautov, Rustem, and Sapontis, James
- Subjects
- *
CHRONIC total occlusion , *PERCUTANEOUS coronary intervention , *ANGINA pectoris , *MYOCARDIAL infarction - Abstract
The percutaneous management of chronic total occlusions (CTO) is a well-established sub-specialty of Interventional Cardiology, requiring specialist equipment, training, and techniques. The heterogeneity of approaches in CTO has led to the generation of multiple algorithms to guide operators in their management. The evidence base for management of CTOs has suffered from inconsistent descriptive and quantitative terminology in defining the nature of lesions and techniques utilised, as well as seemingly contradictory data about improvement in ventricular function, symptoms of angina, and mortality from large-scale registries and randomised controlled trials. Through this review, we explore the history of CTO management and its supporting evidence in detail, with an outline of limitations of CTO-percutaneous coronary intervention and a look at the future of this growing field within cardiology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. Prevalence and impact of depression and anxiety among older myocardial infarction survivors: A nationwide cohort study.
- Author
-
Cha, Seungwoo, Chang, Won Kee, Lee, Kyuna, Han, Kyungdo, Paik, Nam-Jong, and Kim, Won-Seok
- Subjects
- *
MYOCARDIAL infarction , *ANXIETY , *MENTAL depression , *NATIONAL health insurance , *COHORT analysis , *MOTIVATIONAL interviewing - Abstract
Depression and anxiety may be significant prognostic factors after myocardial infarction (MI). Thus, we investigated depression and anxiety prevalence among older MI survivors and their impact on mortality, stroke, and recurrent MI. This population-based cohort study used the Korean National Health Insurance Service database for data concerning individuals aged 66 years who participated in the National Screening Program from 2009 to 2016. Overall, 11,721 individuals with MI history and 58,605 age- and sex-matched controls were included and followed up until 2019. The presence of depression and anxiety was assessed 2 years before and after participation in the program. Mortality and major adverse outcomes, defined as a composite outcome comprising mortality, stroke, and recurrent MI, were analyzed. Depression and anxiety prevalence among MI survivors was 20.4 % and 30.3 %, respectively. Crude odds ratios for depression and anxiety, compared with the control group, were 1.207 (1.148–1.269) and 1.078 (1.032–1.126), respectively. During the follow-up, individuals with depression, anxiety, or both showed increased hazard ratios (HRs) for mortality and major adverse outcomes; after adjustments, their HRs were 1.442 (1.182–1.759), 1.129 (0.960–1.328), and 1.498 (1.263–1.776), respectively, for mortality and 1.505 (1.289–1.758), 1.158 (1.021–1.314), and 1.530 (1.337–1.751), respectively, for major adverse outcomes. Although this was a nationwide cohort study, the MI, depression, and anxiety diagnoses were based on diagnostic codes. Higher depression and anxiety prevalence was observed among older MI survivors. Depression and anxiety occurrence correlated with increased adverse clinical outcomes after adjustments. [Display omitted] • A higher prevalence of depression and anxiety was observed in older myocardial infarction (MI) survivors. • The presence of depression and anxiety was associated with adverse clinical outcomes. • Cardiac rehabilitation models should prioritize the identification and management of depression and anxiety after MI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. The impact of gender on outcomes of transcatheter aortic valve implantation between self-expanding valve and balloon-expandable valve.
- Author
-
Tateishi, Kazuya, Hmoud, Hosam, De Gregorio, Isabella, Hastings, Ramin, and De Gregorio, Joseph
- Subjects
- *
HEART valve prosthesis implantation , *MAJOR adverse cardiovascular events , *VALVES , *DISEASE risk factors , *VASCULAR surgery , *MYOCARDIAL infarction - Abstract
While females have been found to have a higher rate of procedural complications with transcatheter aortic valve implantation (TAVI) than males, the effect of valve choice has not been fully elucidated. This study aimed to investigate the impact of gender and choice of balloon or self-expanding valve on TAVI complications. Data from patients who received a TAVI in our institution from January 2016 to September 2021 were retrospectively analyzed. A total of 971 patients were included and divided into self-expanding valve (n = 315) and balloon-expandable valve (n = 656) groups. The endpoints were 30-day mortality, need for a new pacemaker, and major adverse cardiovascular events (MACE) which is defined as cardiac arrest, stroke, myocardial infarction, major bleeding, and unplanned vascular surgery/intervention. There were more females in the self-expanding valve group than in the balloon-expandable valve group (64.1 % vs. 43.6 %: p < 0.0001). There is no significant difference in the prevalence of hypertension, diabetes mellitus, current smoker, hemodialysis, and the STS risk score between the 2 groups. Females had a higher rate of major adverse cardiovascular events (3.7 % in men vs. 6.8 % in women; p = 0.043), which was driven mostly by vascular complications. This difference was particularly observed in the self-expanding valve group (2.7 % in men vs. 9.4 % in women; p = 0.036). TAVI complications were more common in females than males, driven mostly by vascular complications. This difference was particularly observed in woman treated with a self-expanding valve. Particular attention should be given to access choices in females undergoing TAVI. • We investigated the impact of gender and type of TAVI valve on complications. • Vascular complication was more common in females than males. • This gender difference was mainly observed in patients with self-expanding valve. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Enhancing mass spectrometry data analysis: A novel framework for calibration, outlier detection, and classification.
- Author
-
Peng, Weili, Zhou, Tao, and Chen, Yuanyuan
- Subjects
- *
OUTLIER detection , *TRANSFORMER models , *AUTOMATIC classification , *CORONARY disease , *MYOCARDIAL infarction - Abstract
Mass spectrometry (MS) is a powerful analytical technique in metabolomics, enabling the identification and quantification of metabolites. However, analyzing MS data poses challenges such as batch effects, outliers, and high-dimensional data. In this paper, we propose a comprehensive framework for MS data analysis. The framework integrates data calibration, outlier detection, and automatic classification modules. Data calibration is performed using a deep autoencoder to remove batch effects. Outlier detection combines multiple algorithms through ensemble learning to identify and remove outliers. Automatic classification utilizes a transformer model to handle high-dimensional data and capture global feature relationships. Experimental results on myocardial infarction (MI) and coronary heart disease (CHD) datasets demonstrate the effectiveness of the framework. It outperforms traditional classification models and achieves higher accuracy. The proposed framework provides a robust solution for MS data analysis, facilitating more accurate classification and enabling reliable biological insights in metabolomics research. [Display omitted] • Novel framework integrates three steps for MS data analysis. • Deep AE removes batch effects, while an ensemble approach removes outliers. • Transformer captures intrinsic relationships in MS data for accurate classification. • The framework provides a comprehensive solution to improve classification accuracy. • The framework also facilitates reliable biological insights. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Small extracellular vesicle-mediated CRISPR-Cas9 RNP delivery for cardiac-specific genome editing.
- Author
-
Mun, Dasom, Kang, Ji-Young, Kim, Hyoeun, Yun, Nuri, and Joung, Boyoung
- Subjects
- *
GENOME editing , *CRISPRS , *BAX protein , *NUCLEOPROTEINS , *GENE therapy , *MYOCARDIAL infarction , *DRUG delivery systems , *PEPTIDES - Abstract
Myocardial infarction (MI) is a major cause of morbidity and mortality worldwide. Although clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) gene editing holds immense potential for genetic manipulation, its clinical application is hindered by the absence of an efficient heart-targeted drug delivery system. Herein, we developed CRISPR-Cas9 ribonucleoprotein (RNP)-loaded extracellular vesicles (EVs) conjugated with cardiac-targeting peptide (T) for precise cardiac-specific genome editing. RNP complexes containing Cas9 and single guide RNA targeting miR-34a, an MI-associated molecular target, were loaded into EVs (EV@RNP). Gene editing by EV@RNP attenuated hydrogen peroxide-induced apoptosis in cardiomyocytes via miR-34a inhibition, evidenced by increased B-cell lymphoma 2 levels, decreased Bcl-2-associated X protein levels, and the cleavage of caspase-3. Additionally, to improve cardiac targeting in vivo , we used click chemistry to form functional T-EV@RNP by conjugating T peptides to EV@RNP. Consequently, T-EV@RNP-mediated miR-34a genome editing might exert a protective effect against MI, reducing apoptosis, ameliorating MI injury, and facilitating the recovery of cardiac function. In conclusion, the genome editing delivery system established by loading CRISPR/Cas9 RNP with cardiac-targeting EVs is a powerful approach for precise and tissue-specific gene therapy for cardiovascular disease. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Association of preoperative beta-blocker use and cardiac complications after major noncardiac surgery: a prospective cohort study.
- Author
-
Glarner, Noemi, Puelacher, Christian, Gualandro, Danielle M., Pargger, Mirjam, Huré, Gabrielle, Maiorano, Silvia, Strebel, Ivo, Fried, Simona, Bolliger, Daniel, Steiner, Luzius A., Lampart, Andreas, Lurati Buse, Giovanna, Mujagic, Edin, Lardinois, Didier, Kindler, Christoph, Guerke, Lorenz, Schaeren, Stefan, Mueller, Andreas, Clauss, Martin, and Buser, Andreas
- Subjects
- *
DRUG-eluting stents , *MAJOR adverse cardiovascular events , *COHORT analysis , *MYOCARDIAL infarction , *LONGITUDINAL method , *CHRONIC kidney failure - Abstract
Cardiac complications after major noncardiac surgery are common and associated with high morbidity and mortality. How preoperative use of beta-blockers may impact perioperative cardiac complications remains unclear. In a multicentre prospective cohort study, preoperative beta-blocker use was ascertained in consecutive patients at elevated cardiovascular risk undergoing major noncardiac surgery. Cardiac complications were prospectively monitored and centrally adjudicated by two independent experts. The primary endpoint was perioperative myocardial infarction or injury attributable to a cardiac cause (cardiac PMI) within the first three postoperative days. The secondary endpoints were major adverse cardiac events (MACE), defined as a composite of myocardial infarction, acute heart failure, life-threatening arrhythmia, and cardiovascular death and all-cause death after 365 days. We used inverse probability of treatment weighting to account for differences between patients receiving beta-blockers and those who did not. A total of 3839/10 272 (37.4%) patients (mean age 74 yr; 44.8% female) received beta-blockers before surgery. Patients on beta-blockers were older, and more likely to be male with established cardiorespiratory and chronic kidney disease. Cardiac PMI occurred in 1077 patients, with a weighted odds ratio of 1.03 (95% confidence interval [CI] 0.94–1.12, P =0.55) for patients on beta-blockers. Within 365 days of surgery, 971/10 272 (9.5%) MACE had occurred, with a weighted hazard ratio of 0.99 (95% CI 0.83–1.18, P =0.90) for patients on beta-blockers. Preoperative use of beta-blockers was not associated with decreased cardiac complications including cardiac perioperative myocardial infarction or injury and major adverse cardiac event. Additionally, preoperative use of beta-blockers was not associated with increased all-cause death within 30 and 365 days. NCT02573532. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. The burden of cardiovascular disease and risk for subsequent major adverse cardiovascular events in survivors of childhood cancer: a prospective, longitudinal analysis from the St Jude Lifetime Cohort Study.
- Author
-
Hammoud, Rawan A, Liu, Qi, Dixon, Stephanie B, Onerup, Aron, Mulrooney, Daniel A, Huang, I-Chan, Jefferies, John L, Rhea, Isaac B, Ness, Kirsten K, Ehrhardt, Matthew J, Hudson, Melissa M, Ky, Bonnie, Bhakta, Nickhill, Sapkota, Yadav, Yasui, Yutaka, and Armstrong, Gregory T
- Subjects
- *
MAJOR adverse cardiovascular events , *MYOCARDIAL infarction , *CHILDHOOD cancer , *CANCER fatigue , *CARDIOVASCULAR diseases , *LEFT ventricular dysfunction , *CARDIOVASCULAR diseases risk factors - Abstract
The effect of the increasing lifetime burden of non-major cardiovascular conditions on risk for a subsequent major adverse cardiovascular event among survivors of childhood cancer has not been assessed. We aimed to characterise the prevalence of major adverse cardiovascular events and their association with the cumulative burden of non-major adverse cardiovascular events in childhood cancer survivors. This is a longitudinal cohort study with participant data obtained from an ongoing cohort study at St Jude Children's Research Hospital: the St Jude Lifetime Cohort Study (SJLIFE). Prospective clinical follow-up was of 5-year survivors of childhood cancer who were diagnosed when aged younger than 25 years from 1962 to 2012. Age-frequency, sex-frequency, and race-frequency matched community-control participants completed a similar one-time clinical assessment. 22 cardiovascular events were graded using a St Jude Children's Research Hospital-modified version of the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03). Cumulative incidence and burden of the primary outcome of major adverse cardiovascular events (cardiomyopathy, myocardial infarction, stroke, and other cardiovascular-related mortality) were estimated. Rate ratios (RR) of the association of major adverse cardiovascular events with 22 non-major adverse cardiovascular events were estimated using multivariable piecewise-exponential regression adjusting for attained age, age at diagnosis, sex, race and ethnicity, treatment era, diagnosis of diabetes, and exposure to cardiotoxic cancer therapies. The St Jude Lifetime Cohort study is registered with ClinicalTrials.gov , NCT00760656 , and is ongoing. 9602 5-year survivors of childhood cancer, and 737 community controls were included in the longitudinal follow-up (from Sept 13, 2007, to Dec 17, 2021). The median follow-up was 20·3 years (IQR 12·0–31·4) from the date of primary cancer diagnosis (4311 [44.9%] were females). By the age of 50 years (analysis stopped at age 50 years due to the low number of participants older than that age), the cumulative incidence of major adverse cardiovascular events among survivors was 17·7% (95% CI 15·9–19·5) compared with 0·9% (0·0–2·1) in the community controls. The cumulative burden of major adverse cardiovascular events in survivors was 0·26 (95% CI 0·23–0·29) events per survivor compared with 0·009 (0·000–0·021) events per community control participant. Increasing cumulative burden of grade 1–4 non-major adverse cardiovascular events was associated with an increased future risk of major adverse cardiovascular events (one condition: RR 4·3, 95% CI 3·1–6·0; p<0·0001; two conditions: 6·6, 4·6–9·5; p<0·0001; and three conditions: 7·7, 5·1–11·4; p<0·0001). Increased risk for major adverse cardiovascular events was observed with specific subclinical conditions (eg, grade 1 arrhythmias [RR 1·5, 95% CI 1·2–2·0; p=0·0017]), grade 2 left ventricular systolic dysfunction (2·2, 1·6–3·1; p<0·0001), grade 2 valvular disorders (2·2, 1·2–4·0; p=0·013), but not grade 1 hypercholesterolaemia, grade 1–2 hypertriglyceridaemia, or grade 1–2 vascular stenosis. Among an ageing cohort of survivors of childhood cancer, the accumulation of non-major adverse cardiovascular events, including subclinical conditions, increased the risk of major adverse cardiovascular events and should be the focus of interventions for early detection and prevention of major adverse cardiovascular events. The US National Cancer Institute and the American Lebanese Syrian Associated Charities. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Direct Comparison of the European Society of Cardiology 0/1-Hour Vs. 0/2-Hour Algorithms in Patients with Acute Chest Pain.
- Author
-
Engström, Agnes, Mokhtari, Arash, and Ekelund, Ulf
- Subjects
- *
CHEST pain , *MYOCARDIAL infarction , *DISEASE risk factors , *ALGORITHMS , *CARDIOLOGY - Abstract
The recent guidelines from the European Society of Cardiology recommends using high-sensitivity cardiac troponin (hs-cTn) in either 0/1-h or 0/2-h algorithms to identify or rule out acute myocardial infarction (AMI). Several studies have reported good diagnostic accuracy with both algorithms, but few have compared the algorithms directly. We aimed to compare the diagnostic accuracy of the algorithms head-to-head, in the same patients. This was a secondary analysis of data from a prospective observational study; 1167 consecutive patients presenting with chest pain to the emergency department at Skåne University Hospital (Lund, Sweden) were enrolled. Only patients with a hs-cTnT sample at presentation AND after 1 AND 2 h were included in the analysis. We compared sensitivity, specificity, and negative (NPV) and positive predictive value (PPV). The primary outcome was index visit AMI. A total of 710 patients were included, of whom 56 (7.9%) had AMI. Both algorithms had a sensitivity of 98.2% and an NPV of 99.8% for ruling out AMI, but the 0/2-h algorithm ruled out significantly more patients (69.3% vs. 66.2%, p < 0.001). For rule-in, the 0/2-h algorithm had higher PPV (73.4% vs. 65.2%) and slightly better specificity (97.4% vs. 96.3%, p = 0.016) than the 0/1-h algorithm. Both algorithms had good diagnostic accuracy, with a slight advantage for the 0/2-h algorithm. Which algorithm to implement may thus depend on practical issues such as the ability to exploit the theoretical time saved with the 0/1-h algorithm. Further studies comparing the algorithms in combination with electrocardiography, history, or risk scores are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Personalized Intervention Based on Early Detection of Atherosclerosis: JACC State-of-the-Art Review.
- Author
-
Nielsen, Rikke V., Fuster, Valentin, Bundgaard, Henning, Fuster, Jose J., Johri, Amer M., Kofoed, Klaus F., Douglas, Pamela S., Diederichsen, Axel, Shapiro, Michael D., Nicholls, Stephen J., Nordestgaard, Børge G., Lindholt, Jes S., MacRae, Calum, Yuan, Chun, Newby, David E., Urbina, Elaine M., Bergström, Göran, Ridderstråle, Martin, Budoff, Matthew J., and Bøttcher, Morten
- Subjects
- *
CARDIOVASCULAR diseases , *ATHEROSCLEROSIS , *MYOCARDIAL infarction , *INDIVIDUALIZED medicine , *POPULATION health , *MEDICAL care - Abstract
Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality worldwide and challenges the capacity of health care systems globally. Atherosclerosis is the underlying pathophysiological entity in two-thirds of patients with CVD. When considering that atherosclerosis develops over decades, there is potentially great opportunity for prevention of associated events such as myocardial infarction and stroke. Subclinical atherosclerosis has been identified in its early stages in young individuals; however, there is no consensus on how to prevent progression to symptomatic disease. Given the growing burden of CVD, a paradigm shift is required—moving from late management of atherosclerotic CVD to earlier detection during the subclinical phase with the goal of potential cure or prevention of events. Studies must focus on how precision medicine using imaging and circulating biomarkers may identify atherosclerosis earlier and determine whether such a paradigm shift would lead to overall cost savings for global health. [Display omitted] • Early-stage subclinical atherosclerosis can be identified in young individuals, but evidence-based strategies are needed to prevent progression of disease and clinical events. • Precision medicine using imaging and circulating biomarkers could facilitate early identification of atherosclerosis and the development of curative interventions. • A paradigm shift based on these principles could reduce the global burden of CVD with enormous implications for population health. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Case Volumes and Outcomes Among Early-Career Interventional Cardiologists in the United States.
- Author
-
Rymer, Jennifer A., Narcisse, Dennis I., Chen, Angel, Wojdyla, Daniel, Ashley, Sarah, Damluji, Abdulla A., Shah, Binita, Nanna, Michael G., Swaminathan, Rajesh, Gutierrez, J. Antonio, Uzendu, Anezi, Nelson, Adam J., Bethel, Garrett, Kearney, Katherine, Jones, W. Schuyler, Rao, Sunil V., and Doll, Jacob A.
- Subjects
- *
MYOCARDIAL infarction , *ST elevation myocardial infarction , *PERCUTANEOUS coronary intervention , *CAREER changes , *CARDIOLOGISTS , *MEDICAL databases - Abstract
Little is known about the procedural characteristics, case volumes, and mortality rates for early- vs non–early-career interventional cardiologists in the United States. This study examined operator-level data for patients who underwent percutaneous coronary intervention (PCI) between April 2018 and June 2022. Data were collected from the National Cardiovascular Data Registry CathPCI Registry, American Board of Internal Medicine certification database, and National Plan and Provider Enumeration System database. Early-career operators were within 5 years of the end of training. Annual case volume, expected mortality and bleeding risk, and observed/predicted mortality and bleeding outcomes were evaluated. A total of 1,451 operators were early career; 1,011 changed their career status during the study; and 6,251 were non–early career. Overall, 514,540 patients were treated by early-career and 2,296,576 patients by non–early-career operators. The median annual case volume per operator was 59 (Q1-Q3: 31-97) for early-career and 57 (Q1-Q3: 28-100) for non–early-career operators. Early-career operators were more likely to treat patients presenting with ST-segment elevation myocardial infarction and urgent indications for PCI (both P < 0.001). The median predicted mortality risk was 2.0% (Q1-Q3: 1.5%-2.7%) for early-career and 1.8% (Q1-Q3: 1.2%-2.4%) for non–early-career operators. The median predicted bleeding risk was 4.9% (Q1-Q3: 4.2%-5.7%) for early-career and 4.4% (Q1-Q3: 3.7%-5.3%) for non–early-career operators. After adjustment, an increased risk of mortality (OR: 1.08; 95% CI: 1.05-1.17; P < 0.0001) and bleeding (OR: 1.08; 95% CI: 1.05-1.12; P < 0.0001) were associated with early-career status. Early-career operators are caring for patients with more acute presentations and higher predicted risk of mortality and bleeding compared with more experienced colleagues, with modestly worse outcomes. These data should inform institutional practices to support the development of early-career proceduralists. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Ventricular Septal Rupture After Myocardial Infarction: JACC Focus Seminar 3/5.
- Author
-
Cubeddu, Roberto J., Lorusso, Roberto, Ronco, Daniele, Matteucci, Matteo, Axline, Michael S., and Moreno, Pedro R.
- Subjects
- *
VENTRICULAR septal rupture , *CARDIOGENIC shock , *MYOCARDIAL infarction , *MEDICAL ethics , *ARTIFICIAL blood circulation , *THERAPEUTICS , *HEART assist devices , *THROMBOLYTIC therapy - Abstract
Ventricular septal rupture remains a dreadful complication of acute myocardial infarction. Although less commonly observed than during the prethrombolytic era, the condition remains complex and is often associated with refractory cardiogenic shock and death. Corrective surgery, although superior to medical treatment, has been associated with high perioperative morbidity and mortality. Transcatheter closure techniques are less invasive to surgery and offer a valuable alternative, particularly in patients with cardiogenic shock. In these patients, percutaneous mechanical circulatory support represents a novel opportunity for immediate stabilization and preserved end-organ function. Multimodality imaging can identify favorable septal anatomy for the most appropriate type of repair. The heart team approach will define optimal timing for surgery vs percutaneous repair. Emerging concepts are proposed for a deferred treatment approach, including orthotropic heart transplantation in ideal candidates. Finally, for futile situations, palliative care experts and a medical ethics team will provide the best options for end-of-life clinical decision making. [Display omitted] • The incidence of ventricular septal rupture after acute myocardial infarction has declined, yet there has been little improvement in clinical outcomes. • Corrective surgery and percutaneous septal closure are options for patients with severe hemodynamic derangement. • Collaboration among members of an interdisciplinary heart/shock team can help estimate the chances of viability vs futility, determine the role of mechanical circulatory support, and determine the timing of intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Ventricular Pseudoaneurysm and Free Wall Rupture After Acute Myocardial Infarction: JACC Focus Seminar 4/5.
- Author
-
Lorusso, Roberto, Cubeddu, Roberto J., Matteucci, Matteo, Ronco, Daniele, and Moreno, Pedro R.
- Subjects
- *
MYOCARDIAL infarction , *CARDIAC tamponade , *FALSE aneurysms , *ASYMPTOMATIC patients , *CARDIAC imaging - Abstract
Postinfarction ventricular free-wall rupture is a rare mechanical complication, accounting for <0.01% to 0.02% of cases. As an often-catastrophic event, death typically ensues within minutes due to sudden massive hemopericardium resulting in cardiac tamponade. Early recognition is pivotal, and may allow for pericardial drainage and open surgical repair as the only emergent life-saving procedure. In cases of contained rupture with pseudo-aneurysm (PSA) formation, hospitalization with subsequent early surgical intervention is warranted. Not uncommonly, PSA may go unrecognized in asymptomatic patients and diagnosed late during subsequent cardiac imaging. In these patients, the unsettling risk of complete rupture demands early surgical repair. Novel developments, in the field of transcatheter-based therapies and multimodality imaging, have enabled percutaneous PSA repair as a feasible alternate strategy for patients at high or prohibitive surgical risk. Contemporary advancements in the diagnosis and treatment of postmyocardial infarction ventricular free-wall rupture and PSA are provided in this review. [Display omitted] • Ventricular free-wall rupture is a rare, but potentially fatal, complication of acute myocardial infarction, requiring prompt surgical intervention. • Pseudoaneurysm formation results from contained rupture; characterization by multimodality imaging can enhance risk stratification and guide the surgical strategy. • Developments in transcatheter therapeutics have introduced percutaneous approaches for high-risk or inoperable patients with suitable pathoanatomy, but experience with these options is limited. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Postmyocardial Infarction Ventricular Aneurysm: JACC Focus Seminar 5/5.
- Author
-
Lorusso, Roberto, Matteucci, Matteo, Lerakis, Stamatios, Ronco, Daniele, Menicanti, Lorenzo, Sharma, Samin K., and Moreno, Pedro R.
- Subjects
- *
ARRHYTHMIA , *MYOCARDIAL infarction , *VENTRICULAR arrhythmia , *CONGESTIVE heart failure , *HEART failure , *CORONARY artery bypass - Abstract
Ventricular aneurysm represents a rare complication of transmural acute myocardial infarction, although other cardiac, congenital, or metabolic diseases may also predispose to such condition. Ventricular expansion includes all the cardiac layers, usually with a large segment involved. Adverse events include recurrent angina, reduced ventricular stroke volume with congestive heart failure, mitral regurgitation, thromboembolism, and ventricular arrhythmias. Multimodality imaging is paramount to provide comprehensive assessment, allowing for appropriate therapeutic decision-making. When indicated, surgical intervention remains the gold standard, although additional therapy (heart failure, anticoagulation, and advanced antiarrhythmic treatment) might be required. However, the STICH (Surgical Treatment for Ischemic Heart Failure) trial did not show any advantage from adding surgical ventricular reconstruction to coronary artery bypass surgery in terms of survival, rehospitalization or symptoms, compared with revascularization alone. Finally, implantable cardiac defibrillator may reduce the risk of fatal arrhythmias. [Display omitted] • Acute myocardial infarction is the most frequent cause of left ventricular aneurysm formation, although genetic, metabolic, inflammatory, and traumatic conditions are additional etiologies. • Angina, heart failure, thromboembolism, and ventricular arrhythmias are potential complications requiring specific therapies, including surgical reconstruction, anticoagulation, ablation of arrhythmias, implantable devices, and pharmacological therapy. • In patients with ventricular aneurysm complicated by ventricular tachycardia, implanted cardioverter-defibrillators may reduce the risk of sudden death. Electrophysiological mapping is critical to determining whether to pursue surgical or percutaneous ablation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Uniform or Sex-Specific Cardiac Troponin Thresholds to Rule Out Myocardial Infarction at Presentation.
- Author
-
Li, Ziwen, Wereski, Ryan, Anand, Atul, Lowry, Matthew T.H., Doudesis, Dimitrios, McDermott, Michael, Ferry, Amy V., Tuck, Chris, Chapman, Andrew R., Lee, Kuan Ken, Shah, Anoop S.V., Mills, Nicholas L., and Kimenai, Dorien M.
- Subjects
- *
MYOCARDIAL infarction , *TROPONIN , *PATIENTS , *TROPONIN I , *HOSPITAL admission & discharge , *DEATH rate - Abstract
Myocardial infarction can be ruled out in patients with a single cardiac troponin measurement. Whether use of a uniform rule-out threshold has resulted in sex differences in care remains unclear. The purpose of this study was to evaluate implementation of a uniform rule-out threshold in females and males with possible myocardial infarction, and to derive and validate sex-specific thresholds. The implementation of a uniform rule-out threshold (<5 ng/L) with a high-sensitivity cardiac troponin I assay was evaluated in consecutive patients presenting with possible myocardial infarction. The proportion of low-risk patients discharged from the emergency department and incidence of myocardial infarction or cardiac death at 30 days were determined. Sex-specific thresholds were derived and validated, and proportion of female and male patients were stratified as low-risk compared with uniform threshold. In 16,792 patients (age 58 ± 17 years; 46% female) care was guided using a uniform threshold. This identified more female than male patients as low risk (73% vs 62%), but a similar proportion of low-risk patients were discharged from the emergency department (81% for both) with fewer than 5 (<0.1%) patients having a subsequent myocardial infarction or cardiac death at 30 days. Compared with a uniform threshold of <5 ng/L, use of sex-specific thresholds would increase the proportion of female (61.8% vs 65.9%) and reduce the proportion of male (54.8% vs 47.8%) patients identified as low risk. Implementation of a uniform rule-out threshold for myocardial infarction was safe and effective in both sexes. Sex-specific rule-out thresholds should be considered, but their impact on effectiveness and safety may be limited. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. JACC Focus Seminar on Mechanical Complications of Acute Myocardial Infarction.
- Author
-
Moreno, Pedro R. and Fuster, Valentin
- Subjects
- *
MYOCARDIAL infarction , *VENTRICULAR septal rupture , *ARTIFICIAL blood circulation , *MUSCLE injuries , *PAPILLARY muscles - Published
- 2024
- Full Text
- View/download PDF
41. Can Plaque Imaging Improve Risk Assessment Among Individuals With Elevated Lp(a)?
- Author
-
Blankstein, Ron and Shiyovich, Arthur
- Subjects
- *
RISK assessment , *MYOCARDIAL infarction , *CORONARY artery disease , *ATHEROSCLEROTIC plaque - Abstract
[Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
42. Association of Lipoprotein(a) Levels With Myocardial Infarction in Patients With Low-Attenuation Plaque.
- Author
-
Yu, Meng-Meng, Wang, Ming-Liang, Wang, Jin-Jin, Lin, Bo-Li, Zhao, Xin, Tao, Xin-Wei, Chen, Yin-Yin, Li, Peng-Yang, Zhang, Jing-Kun, Ge, Jun-Bo, Jin, Hang, and Zeng, Meng-Su
- Subjects
- *
MYOCARDIAL infarction , *PROPORTIONAL hazards models , *CORONARY artery disease , *COMPUTED tomography - Abstract
Lipoprotein(a) (Lp[a]) is associated with an increased risk of myocardial infarction (MI). However, the mechanism underlying this association has yet to be fully elucidated. This multicenter study aimed to investigate whether association between Lp(a) and MI risk is reinforced by the presence of low-attenuation plaque (LAP) identified by coronary computed tomography angiography (CCTA). In a derivation cohort, a total of 5,607 patients with stable chest pain suspected of coronary artery disease who underwent CCTA and Lp(a) measurement were prospectively enrolled. In validation cohort, 1,122 patients were retrospectively collected during the same period. High Lp(a) was defined as Lp(a) ≥50 mg/dL. The primary endpoint was a composite of time to fatal or nonfatal MI. Associations were estimated using multivariable Cox proportional hazard models. During a median follow-up of 8.2 years (Q1-Q3: 7.2-9.3 years), the elevated Lp(a) levels were associated with MI risk (adjusted HR [aHR]: 1.91; 95% CI: 1.46-2.49; P < 0.001). There was a significant interaction between Lp(a) and LAP (P interaction <0.001) in relation to MI risk. When stratified by the presence or absence of LAP, Lp(a) was associated with MI in patients with LAP (aHR: 3.03; 95% CI: 1.92-4.76; P < 0.001). Mediation analysis revealed that LAP mediated 73.3% (P < 0.001) for the relationship between Lp(a) and MI. The principal findings remained unchanged in the validation cohort. Elevated Lp(a) augmented the risk of MI during 8 years of follow-up, especially in patients with LAP identified by CCTA. The presence of LAP could reinforce the relationship between Lp(a) and future MI occurrence. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5.
- Author
-
Estévez-Loureiro, Rodrigo, Lorusso, Roberto, Taramasso, Maurizio, Torregrossa, Gianluca, Kini, Annapoorna, and Moreno, Pedro R.
- Subjects
- *
MYOCARDIAL infarction , *CARDIOGENIC shock , *MITRAL valve insufficiency , *ARTIFICIAL blood circulation , *HEART failure , *MUSCLE injuries , *PAPILLARY muscles - Abstract
Severe acute mitral regurgitation after myocardial infarction includes partial and complete papillary muscle rupture or functional mitral regurgitation. Although its incidence is <1%, mitral regurgitation after acute myocardial infarction frequently causes hemodynamic instability, pulmonary edema, and cardiogenic shock. Medical management has the worst prognosis, and mortality has not changed in decades. Surgery represents the gold standard, but it is associated with high rates of morbidity and mortality. Recently, transcatheter interventions have opened a new door for management that may improve survival. Mechanical circulatory support restores vital organ perfusion and offers the opportunity for a steadier surgical repair. This review focuses on the diagnosis and the interventional management, both surgical and transcatheter, with a glance on future perspectives to enhance patient management and eventually decrease mortality. [Display omitted] • Severe MR developing early after MI is associated with increased risks of heart failure and mortality. • Although surgical treatment can improve survival, the incidence of adverse events and mortality remain high. • Early mechanical cardiac support and transcatheter repair techniques can expand treatment options to a broader population and potentially improve outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Right Ventricular Myocardial Infarction—A Tale of Two Ventricles: JACC Focus Seminar 1/5.
- Author
-
Goldstein, James A., Lerakis, Stamatios, and Moreno, Pedro R.
- Subjects
- *
CARDIOGENIC shock , *MYOCARDIAL infarction , *ARTIFICIAL blood circulation , *VENTRICULAR septum , *VENTRICULAR arrhythmia - Abstract
Right ventricular infarction (RVI) complicates 50% of cases of acute inferior ST-segment elevation myocardial infarction, and is associated with high in-hospital morbidity and mortality. Ischemic right ventricular (RV) systolic dysfunction decreases left ventricular preload delivery, resulting in low-output hypotension with clear lungs, and disproportionate right heart failure. RV systolic performance is generated by left ventricular contractile contributions mediated by the septum. Augmented right atrial contraction optimizes RV performance, whereas very proximal occlusions induce right atrial ischemia exacerbating hemodynamic compromise. RVI is associated with vagal mediated bradyarrhythmias, both during acute occlusion and abruptly with reperfusion. The ischemic dilated RV is also prone to malignant ventricular arrhythmias. Nevertheless, RV is remarkably resistant to infarction. Reperfusion facilitates RV recovery, even after prolonged occlusion and in patients with severe shock. However, in some cases hemodynamic compromise persists, necessitating pharmacological and mechanical circulatory support with dedicated RV assist devices as a "bridge to recovery." [Display omitted] • RVI results from proximal RCA occlusion, occurs in approximately 50% of patients with inferior MI, and is associated with increased in-hospital morbidity and mortality due to shock and arrhythmias. • Augmented RA contraction optimizes RV performance. Reperfusion facilitates RV recovery and improves outcomes, even after prolonged occlusion and in patients with ventricular shock. • Shock in patients with RVI reduces LV preload, and involvement of the interventricular septum adversely affects LV function. Patients with persistent hemodynamic compromise may benefit from pharmacological and mechanical circulatory support. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Recent advances in potential targets for myocardial ischemia reperfusion injury: Role of macrophages.
- Author
-
Zhuang, Qigang, Li, Mingyue, Hu, Desheng, and Li, Junyi
- Subjects
- *
MYOCARDIAL reperfusion , *REPERFUSION injury , *MYOCARDIAL ischemia , *MACROPHAGES , *MYOCARDIAL infarction , *TOLL-like receptors - Abstract
Myocardial ischemia-reperfusion injury (MIRI) is a complex process that occurs when blood flow is restored after myocardium infarction (MI) with exacerbated tissue damage. Macrophages, essential cell type of the immune response, play an important role in MIRI. Macrophage subpopulations, namely M1 and M2, are distinguished by distinct phenotypes and functions. In MIRI, macrophages infiltrate in infarcted area, shaping the inflammatory response and influencing tissue healing. Resident cardiac macrophages interact with monocyte-derived macrophages in MIRI, and influence injury progression. Key factors including chemokines, cytokines, and toll-like receptors modulate macrophage behavior in MIRI. This review aims to address recent findings on the classification and the roles of macrophages in the myocardium, spanning from MI to subsequent MIRI, and highlights various signaling pathways implicated in macrophage polarization underlining the complexity of MIRI. This article will shed light on developing advanced therapeutic strategies for MIRI management. • Modulation of macrophage polarization as a potential target for treating Myocardial Ischemia Reperfusion Injury (MIRI). • Summary for cell types of macrophages and their function. • Localization & phenotypes of macrophages in myocardial tissue. • Conclusion for recent researches of the potential mechanism of macrophages during myocardial infarction (MI) & MIRI. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. The lowest well tolerated blood pressure: A personalized target for all?
- Author
-
Verdecchia, Paolo, Angeli, Fabio, and Reboldi, Gianpaolo
- Subjects
- *
BLOOD pressure , *CARDIOLOGICAL manifestations of general diseases , *AMBULATORY blood pressure monitoring , *HYPERTENSION , *KIDNEY diseases , *CARDIOVASCULAR diseases risk factors - Abstract
• The definition of optimal blood pressure (BP) target for prevention of cardiovascular complications of hypertension remains uncertain. • Randomized strategy trials comparing lower (i.e., more intensive) versus higher (i.e., less intensive) BP targets should drive the definition, but these trials were extremely heterogeneous by testing different BP targets based on systolic BP, diastolic BP or combined systolic and diastolic BP goals. • The more intensive treatment targets reduced the risk of major cardiovascular complications of hypertension when compared with the less intensive targets, despite a higher incidence of unwanted effects. • Given the heterogeneity of available data in support to fixed BP targets, their definition should be personalized not only in frail patients, but in all patients and based on best trade-off between efficacy and safety, i.e., the lowest well tolerated BP. The optimal blood pressure (BP) target for prevention of cardiovascular complications of hypertension remains uncertain. Most Guidelines suggest different targets depending on age, comorbidities and treatment tolerability, but the underlying evidence is not strong. Results of randomized strategy trials comparing lower (i.e., more intensive) versus higher (i.e., less intensive) BP targets should drive the definition. However, these trials tested different BP targets based on systolic BP, diastolic BP or combined systolic and diastolic BP goals. Overall, the more intensive treatment targets reduced the risk of major cardiovascular complications of hypertension when compared with the less intensive targets, despite a higher incidence of unwanted effects including, but not limited to, hypotension, electrolyte abnormalities and renal dysfunction. Consequently, some Guidelines defined low BP thresholds (i.e., 120/70 mmHg) not to exceed downward because of the expectation that unwanted effects may outweigh the outcome benefits. The present review discusses the evidence underlying the choice of BP targets, which remains an important step in the management of hypertensive patients. We conclude that, on the ground of the heterogeneity of available data in support to fixed BP targets, their definition should be personalized in all patients and based on best trade-off between efficacy and safety, i.e., the lowest well tolerated BP. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Atherosclerotic Cardiovascular Events in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Retrospective Cohort Study.
- Author
-
Tan, Sean, Spear, Ella, Sane, Nikhita, Chan, Jasmine, Nelson, Adam J., Alamgeer, Muhammad, Nerlekar, Nitesh, Segelov, Eva, and Nicholls, Stephen J.
- Subjects
- *
IMMUNE checkpoint inhibitors , *CANCER patients , *ISCHEMIC stroke , *MYOCARDIAL infarction , *CARDIOVASCULAR diseases risk factors , *ALTEPLASE - Abstract
Immune checkpoint inhibitors (ICIs) are effective therapies for numerous cancers, but have been associated with atherosclerotic cardiovascular disease (ASCVD). This study aimed to identify predictors for ASCVD events among cancer patients treated with ICIs and the cardiovascular risk factor (CVRF) control of those who developed ASCVD. A single-centre retrospective study of 366 cancer patients who received ICIs from 2018 to 2020 was performed. Demographic, baseline CVRF, cancer history, and ICI regimen data were obtained from medical records. The primary end point of ASCVD events was defined as myocardial infarction, coronary revascularisation, ischaemic stroke, or acute limb ischaemia. Cox proportional multivariable modelling and competing risks analysis were performed to assess ASCVD predictors. Descriptive analysis was performed to describe CVRF management among those who developed ASCVD events. Over a median follow-up of 3.4 years (2.8–4.3), 26 patients (7.1%) experienced 27 ASCVD events (seven myocardial infarction, one coronary revascularisation, 13 ischaemic stroke, and six acute limb ischaemia events). There were 226 (61.8%) cancer-related deaths and no cardiac deaths. History of ASCVD before ICI initiation was independently associated with ASCVD events on traditional Cox modelling (hazard ratio [HR] 4.00; 95% confidence interval [CI] 1.79–8.91; p<0.01) and competing risks analysis (HR 4.23; 95% CI 1.87–9.60; p<0.01). A total of 17 patients developed ASCVD events after ICI cessation (median 1.4 years). Among those with ASCVD events, 12 had prior ASCVD, 16 had hypertension, nine had hypercholesterolaemia, and four had diabetes, and nine were actively smoking. Variable prescription of cardiovascular preventative therapies was noted. History of ASCVD was associated with subsequent ASCVD events among patients treated with ICIs, which could occur even after active treatment was stopped. Identification and aggressive management of modifiable CVRFs should be considered throughout cancer survivorship in patients who received ICI treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. The impact of different co-morbidities on clinical outcomes and resource utilization in critically ill burn and surgical patients: A population-based analysis of social determinants of health.
- Author
-
Lagziel, Tomer, Quiroga, Luis H., Ross, Emily, Khoo, Kimberly H., Shamoun, Feras, Asif, Mohammed, Caffrey, Julie A., and Hultman, C. Scott
- Subjects
- *
BURN patients , *SOCIAL determinants of health , *ST elevation myocardial infarction , *CRITICALLY ill , *SURGICAL intensive care , *BURN care units , *MYOCARDIAL infarction - Abstract
This study aims to establish the significance of social determinants of health and prevalent co-morbidities on multiple indicators for quality of care in patients admitted to the Burn and Surgical Intensive Care Unit (ICU). We performed a retrospective analysis of population group data for patients admitted at the Burn and Surgical ICU from January 1, 2016, to November 18, 2019. The primary outcomes were length of hospital stay (LOS), mortality, 30-day readmission, and hospital charges. Pearson's chi-square test for categorical variables and t-test for continuous variables were used to compare population health groups. We analyzed a total of 487 burn and 510 surgical patients. When comparing ICU patients, we observed significantly higher mean hospital charges and length of stay (LOS) in BICU v. SICU patients with a history of mental health ($93,259.40 v. $50,503.36, p = 0.013 and 16.28 v. 9.16 days, p = 0.0085), end-stage-renal-disease (ESRD) ($653,871.05 v. $75,746.35, p = 0.0047 and 96.15 v. 17.53 days, p = 0.0104), sepsis ($267,979.60 v. $99,154.41, p = <0.001 and 39.1 v. 18.42 days, p = 0.0043), and venous thromboembolism (VTE) ($757,740.50 v. $117,816.40, p = <0.001 and 93.11 v. 20.21 days, p = 0.002). Also, higher mortality was observed in burn patients with ESRD, ST-Elevation Myocardial Infarction (STEMI), sepsis, VTE, and diabetes mellitus. 30-day-readmissions were greater among burn patients with a history of mental health, drug dependence, heart failure, and diabetes mellitus. Our study provides new insights into the variability of outcomes between burn patients treated in different critical care settings, underlining the influence of comorbidities on these outcomes. By comparing burn patients in the BICU with those in the SICU, we aim to highlight how differences in patient backgrounds, including the quality of care received, contribute to these outcomes. This comparison underscores the need for tailored healthcare strategies that consider the unique challenges faced by each patient group, aiming to mitigate disparities in health outcomes and healthcare spending. Further research to develop relevant and timely interventions that can improve these outcomes. • Social factors affect BICU and SICU patients differently. • BICU patients with mental health, renal disease, sepsis, and thrombosis face higher costs and LOS. • BICU patients with renal disease, heart attack, sepsis, thrombosis, and diabetes see higher death rates. • BICU patients with mental health, addiction, heart failure, and diabetes face more readmissions. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Association between depression, antidepressant use, and the incidence of atherosclerotic cardiovascular diseases.
- Author
-
Kim, Hyewon, Lee, You-Bin, Lee, Jungkuk, Kang, Dongwoo, Kim, Gyuri, Jin, Sang-Man, Kim, Jae Hyeon, Hur, Kyu Yeon, and Jeon, Hong Jin
- Subjects
- *
CARDIOVASCULAR diseases , *ANTIDEPRESSANTS , *MYOCARDIAL ischemia , *TRICYCLIC antidepressants , *MENTAL depression - Abstract
To examine the association between depression, the use of antidepressants, and atherosclerotic cardiovascular disease (ASCVD). The South Korean national claims data was used. Among a nationally representative population, 273,656 subjects who had been diagnosed with depression and prescribed antidepressants ("DEP with antidepressants") and 78,851 subjects who had been diagnosed with depression but not prescribed antidepressants ("DEP without antidepressants") were identified to be eligible. Healthy controls (HCs) were 1:1 matched with DEP with antidepressants group for age and sex. We followed up on the occurrence of ASCVD including ischemic heart diseases and ischemic stroke. The risk of ASCVD was increased in the DEP with antidepressants group and decreased in the DEP without antidepressants group compared to HCs. Among those under antidepressants, tricyclic antidepressant users showed the highest risk of ASCVD compared to HCs. Among young adults, the risk of ASCVD was increased in both groups. The risk of ASCVD increased in depression patients taking antidepressants, while it decreased in depression patients not taking antidepressants. However, the relationship showed differences according to drug class and age group. • Depression is a well-known risk factor for atherosclerotic cardiovascular disease. • We examined the risk of ASCVD in depression patients with/without antidepressants. • Depression patients with antidepressants showed an increased risk of ASCVD. • Depression patients without antidepressants showed a decreased risk of ASCVD. • The use of antidepressants, rather than depression, is the risk factor for ASCVD. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Association of antiplatelet therapy with clinical outcomes in patients with peripheral artery disease.
- Author
-
Al-Sadawi, Mohammed, Tao, Michael, Dhaliwal, Simrat, Masson, Ravi, Bhagat, Aditi A., Parikh, Puja B., Lawson, William E., and Reilly, John P.
- Subjects
- *
PERIPHERAL vascular diseases , *MYOCARDIAL infarction , *TREATMENT effectiveness , *CORONARY artery disease , *MORTALITY - Abstract
The beneficial role of dual anti-platelet therapy (DAPT) in coronary artery disease is well established. However, there is limited data describing the effects of DAPT in patients with atherosclerotic peripheral artery disease (PAD). The aim of this meta-analysis is to compare clinical outcomes associated with DAPT versus single anti-platelet therapy (SAPT) in patients with symptomatic PAD. We performed a literature search for studies assessing the risk of adverse cardiovascular and limb events in cohorts receiving either DAPT or SAPT. The primary endpoint was all cause mortality. The secondary endpoints included graft failure, amputation, total bleeding, severe bleeding and fatal bleeding. The search included the following databases: Ovid MEDLINE, EMBASE, Web of Science, and Google Scholar. The search was not restricted to time or publication status. A total of 11 studies with 54,331 participants (24,449 on SAPT and 29,882 on DAPT) were included. Patients with PAD treated with SAPT had higher all-cause mortality compared to patients treated with DAPT (OR 1.37, 95 % CI 1.09–1.74; p < 0.01). There was no difference in risk of graft failure or amputation between patients treated with SAPT or DAPT (OR 0.9, 95 % CI 0.77–1.06; p = 0.19; OR 1.11, 95 % CI 0.88–1.41; p = 0.37). Patients treated with SAPT had lower total bleeds compared to patients treated with DAPT (OR 0.53, 95 % CI 0.36–0.77; p < 0.01). However, For SAPT plus AC vs SAPT, a total of 8 studies with 17,100 participants (3447 with SAPT plus AC and 8619 with only SAPT) were included. Patients on SAPT plus AC did not have a statistically significant difference in risk for all-cause mortality, (OR 0.91, 95 % CI 0.67–1.24; p = 0.56). SAPT plus AC had significantly lower risk of MI (OR 0.82, 95 % CI 0.69–0.97; p = 0.02), amputation (OR 0.72, 95 % CI 0.53–0.97; p = 0.03), and graft failure (OR 0.66, 95 % CI 0.48–0.93; p = 0.02). There was no significant different in risk of fatal bleeding be-tween the two groups (OR 1.60, 95 % CI 0.76–3.35; p = 0.22). In patients with symptomatic PAD, a strategy of DAPT may confer a mortality benefit when compared to SAPT without significantly increasing the risk of serious bleeding events. • In patients with symptomatic PAD, a strategy of DAPT may confer a mortality benefit when compared to SAPT without significantly increasing the risk of serious bleeding events. • SAPT with AC maybe associated with lower risk of MI, amputation and graft failure without incraese risk of fatal bleeds. • Further randomised trials are needed to confirm such findings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.